var title_f35_55_36720="Normal vaginal flora";
var content_f35_55_36720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal vaginal flora",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of vaginal swab under high power magnification (1000x) showing mixed bacterial Gram stain morphology consistent with normal vaginal flora.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36720=[""].join("\n");
var outline_f35_55_36720=null;
var title_f35_55_36721="Posterior lenticonus";
var content_f35_55_36721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior lenticonus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior lenticonus. There is a larger than typical, relatively clear protrusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36721=[""].join("\n");
var outline_f35_55_36721=null;
var title_f35_55_36722="Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity";
var content_f35_55_36722=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"PostTestProb_form\" name=\"PostTestProb_form\" onkeydown=\"clrResults();\" onkeyup=\"PostTestProb_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PostOddsPos = (PreTestProb * Sensitivity) / ((1 - PreTestProb) * (1-Specificity))",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PostTestProbPosResult = PostOddsPos / (1 + PostOddsPos)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PostOddsNeg = (PreTestProb * (1-Sensitivity)) / ((1-PreTestProb) * Specificity)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PostTestProbNegResult = PostOddsNeg / (1 + PostOddsNeg)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Pre Test Prob",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Pre_Test_Prob_param\" onblur=\"PostTestProb_fx(); minMaxCheck();\" onchange=\"PostTestProb_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Pre_Test_Prob_unit\" onchange=\"PostTestProb_fx();\" style=\"width:105px;\">",
"             <option value=\"0.01|0|%\">",
"              %",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|fraction\">",
"              fraction",
"             </option>",
"             <option value=\"1|0|ratio\">",
"              ratio",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Sensitivity",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Sensitivity_param\" onblur=\"PostTestProb_fx(); minMaxCheck();\" onchange=\"PostTestProb_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Sensitivity_unit\" onchange=\"PostTestProb_fx();\" style=\"width:105px;\">",
"             <option value=\"0.01|0|%\">",
"              %",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|fraction\">",
"              fraction",
"             </option>",
"             <option value=\"1|0|ratio\">",
"              ratio",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Specificity",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Specificity_param\" onblur=\"PostTestProb_fx(); minMaxCheck();\" onchange=\"PostTestProb_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Specificity_unit\" onchange=\"PostTestProb_fx();\" style=\"width:105px;\">",
"             <option value=\"0.01|0|%\">",
"              %",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|fraction\">",
"              fraction",
"             </option>",
"             <option value=\"1|0|ratio\">",
"              ratio",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Post Test Prob Pos Result",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Post_Test_Prob_Pos_Result_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"Post_Test_Prob_Pos_Result_unit\" onchange=\"PostTestProb_fx();\" style=\"width:105px;\">",
"              <option value=\"0.01|0|%\">",
"               %",
"              </option>",
"              <option value=\"1|0|fraction\">",
"               fraction",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Post Test Prob Neg Result",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Post_Test_Prob_Neg_Result_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"Post_Test_Prob_Neg_Result_unit\" onchange=\"PostTestProb_fx();\" style=\"width:105px;\">",
"              <option value=\"0.01|0|%\">",
"               %",
"              </option>",
"              <option value=\"1|0|fraction\">",
"               fraction",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|ratio\">",
"               ratio",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"PostTestProb_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option>",
"              2",
"             </option>",
"             <option selected=\"selected\">",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      <b>",
"       Post Test Prob Pos Result",
"      </b>",
"      is the probability that the disease is present when the test result is",
"      <b>",
"       positive",
"      </b>",
"      .",
"     </li>",
"     <li>",
"      <b>",
"       Post Test Prob Neg Result",
"      </b>",
"      is the probability that the disease is present when the test result is",
"      <b>",
"       negative",
"      </b>",
"      .",
"     </li>",
"     <li>",
"      Pre test probability (",
"      <b>",
"       Pre Test Prob",
"      </b>",
"      ) is usually equivalent to the prevalence of a disease or finding in a particular population.",
"     </li>",
"    </ul>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36722=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function PostTestProb_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.PostTestProb_form){",
"",
"",
"doCalc = true;",
"if (Pre_Test_Prob_param.value.indexOf(',') >= 0){ Pre_Test_Prob_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Pre_Test_Prob_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Pre_Test_Prob_unit.options[Pre_Test_Prob_unit.selectedIndex].value.split('|');",
"Pre_Test_Prob = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Sensitivity_param.value.indexOf(',') >= 0){ Sensitivity_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Sensitivity_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Sensitivity_unit.options[Sensitivity_unit.selectedIndex].value.split('|');",
"Sensitivity = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Specificity_param.value.indexOf(',') >= 0){ Specificity_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Specificity_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Specificity_unit.options[Specificity_unit.selectedIndex].value.split('|');",
"Specificity = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"Post_Odds_Pos =  (Pre_Test_Prob * Sensitivity) / ((1 - Pre_Test_Prob) * (1-Specificity));",
"",
"Post_Test_Prob_Pos_Result =  Post_Odds_Pos / (1 + Post_Odds_Pos);",
"",
"unit_parts = Post_Test_Prob_Pos_Result_unit.options[Post_Test_Prob_Pos_Result_unit.selectedIndex].value.split('|');",
"if (doCalc) Post_Test_Prob_Pos_Result_param.value = fixDP((Post_Test_Prob_Pos_Result - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"Post_Odds_Neg =  (Pre_Test_Prob * (1-Sensitivity)) / ((1-Pre_Test_Prob) * Specificity);",
"",
"Post_Test_Prob_Neg_Result =  Post_Odds_Neg / (1 + Post_Odds_Neg);",
"",
"unit_parts = Post_Test_Prob_Neg_Result_unit.options[Post_Test_Prob_Neg_Result_unit.selectedIndex].value.split('|');",
"if (doCalc) Post_Test_Prob_Neg_Result_param.value = fixDP((Post_Test_Prob_Neg_Result - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PostTestProb_form){",
"",
"if (Pre_Test_Prob_param.value && Pre_Test_Prob < 0) {",
"Pre_Test_Prob = 0;",
"Pre_Test_Prob_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Pre Test Prob is 0 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Pre_Test_Prob_param.value && Pre_Test_Prob > 1) {",
"Pre_Test_Prob_param.value = \"\";",
"clrResults();",
"Pre_Test_Prob = 0;",
"doCalc = false;",
"alert(\"The maximum value for Pre Test Prob is 1 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Sensitivity_param.value && Sensitivity < 0) {",
"Sensitivity = 0;",
"Sensitivity_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Sensitivity is 0 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Sensitivity_param.value && Sensitivity > 1) {",
"Sensitivity_param.value = \"\";",
"clrResults();",
"Sensitivity = 0;",
"doCalc = false;",
"alert(\"The maximum value for Sensitivity is 1 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Specificity_param.value && Specificity < 0) {",
"Specificity = 0;",
"Specificity_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Specificity is 0 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Specificity_param.value && Specificity > 1) {",
"Specificity_param.value = \"\";",
"clrResults();",
"Specificity = 0;",
"doCalc = false;",
"alert(\"The maximum value for Specificity is 1 fraction.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PostTestProb_form){",
"",
"Post_Test_Prob_Pos_Result_param.value = '';",
"Post_Test_Prob_Neg_Result_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f35_55_36722=null;
var title_f35_55_36723="Triquetral fractures";
var content_f35_55_36723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Triquetral fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36723/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36723/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36723/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36723/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36723/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36723/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/55/36723/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity fractures are among the most common of the extremity injuries with carpal fractures accounting for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Of these, fractures to bones of the proximal carpal row are most frequent. The triquetrum is reported as the second or third most common carpal fracture representing 3 to 5 percent of all carpal bone injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. It is the second most common carpal fracture in sports.",
"   </p>",
"   <p>",
"    This topic will review issues related to fractures of the triquetrum. A general overview of carpal fractures in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triquetrum is located just distal to the ulna and the triangular fibrocartilage complex and proximal to the base of the hamate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"mobipreview.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69097 \" href=\"mobipreview.htm?1/31/1527\">",
"     figure 1",
"    </a>",
"    ). The triquetrum articulates on its radial side with the lunate to which it is attached by the lunotriquetral ligament. On the volar (palmar) aspect there is an articulation with the pisiform. The anatomy of the wrist is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14039?source=see_link\">",
"     \"Anatomy and basic biomechanics of the wrist\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triquetral fractures typically occur from a hyperextension injury with the wrist in ulnar deviation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/6\">",
"     6",
"    </a>",
"    ]. Shearing forces exerted by the proximal hamate, distal ulna, or both may play a role. Injury can also occur with hyperflexion. In addition, either the dorsal or volar radiotriquetral ligaments may avulse triquetral fragments at their attachments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Triquetral fractures may be divided into two types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chip fractures &ndash; A chip fracture, usually off the dorsal radial surface, typically occurs with a wrist hyperextension injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/4\">",
"       4",
"      </a>",
"      ]. Such fractures account for up to 93 percent of triquetral fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/5\">",
"       5",
"      </a>",
"      ]. Chip fractures can also occur with the hyperflexion mechanism mention previously.",
"     </li>",
"     <li>",
"      Midbody fracture &ndash; Fractures through the midbody of the triquetrum are less common than chip fractures. This type of fracture is usually the result of a direct blow with high energy. They may occur in conjunction with a perilunate dislocation in 12 to 25 percent of triquetral injuries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12632?source=see_link&amp;anchor=H14#H14\">",
"       \"Evaluation of the adult with acute wrist pain\", section on 'Scapholunate dissociation, lunate dislocation, and related injuries'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient typically presents with a history of injury and pain at the ulnar aspect of the wrist. On examination, there is usually pain and point tenderness dorsally or along the ulnar border of the wrist, 1 to 2 cm distal to the most distal aspect of the ulna or the ulnar styloid. Wrist extension may reproduce or exacerbate pain.",
"   </p>",
"   <p>",
"    When palpating the wrist, it may be difficult to elicit focal tenderness solely over the triquetrum given the proximity of the triangular fibrocartilage complex (TFCC) and other ulnar structures, such as the extensor carpi ulnaris tendon and the ulnar styloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/5\">",
"     5",
"    </a>",
"    ]. The triquetrum is most easily palpated with the wrist in radial deviation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anteroposterior (AP), lateral and oblique views of the wrist should be obtained (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59010 graphicRef67772 graphicRef81364 \" href=\"mobipreview.htm?21/21/21844\">",
"     image 2A-C",
"    </a>",
"    ). Avulsion fractures are typically difficult to appreciate on the AP view, but with careful scrutiny, a small radiodense fragment may be seen just dorsal to the proximal row of carpal bones on the lateral view. If a fracture is not identified with the standard three views but clinical suspicion persists, a lateral view with slight pronation (30 to 45 degrees) will reveal the triquetrum dorsal to the lunate. Transverse fractures of the midbody of the triquetrum are usually visualized on an AP view.",
"   </p>",
"   <p>",
"    Volar avulsion fractures, which are much less common, are difficult to visualize with the standard series of radiographs, but may be appreciated on a series of wrist films done to evaluate ligamentous stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/7\">",
"     7",
"    </a>",
"    ]. If radiographs do not demonstrate injury and a definitive diagnosis is needed, computed tomography (CT) scan can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated fractures of the triquetral body are uncommon, but displacement may be underappreciated. CT imaging should be obtained of all triquetral body fractures and all triquetral fractures associated with perilunate dislocations. Fractures displaced &gt;1 mm are referred to a hand surgeon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avulsion fractures are treated with proper immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/4\">",
"     4",
"    </a>",
"    ]. These are generally of little consequence, as most go on to an asymptomatic fibrous union, but they do indicate underlying soft tissue injury that must be allowed to heal with three to six weeks of immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the clinician should be alert to the possibility of other undiagnosed pathology, such as a lunotriquetral ligament tear, pisiform fracture, or injury to the triangular fibrocartilage complex. The presence of such an injury is suggested by marked or persistent swelling, limited wrist motion, or continued pain at the ulnar aspect of the wrist despite demonstrated radiographic healing. In such instances, an arthrogram or MR arthrogram may be used to assess ligamentous disruption and evaluation by a hand surgeon is prudent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is to be referred, a volar splint with the wrist in slight dorsiflexion and the metacarpophalangeal (MCP) joint free (",
"    <a class=\"graphic graphic_figure graphicRef65696 \" href=\"mobipreview.htm?42/15/43263\">",
"     figure 2",
"    </a>",
"    ) provides protection while allowing for icing and elevation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient has a chip, avulsion, or non-displaced body fracture, a short arm cast with the wrist in slight extension can be placed, generally",
"    <strong>",
"     after",
"    </strong>",
"    three to four days to allow swelling to subside.",
"   </p>",
"   <p>",
"    Guidelines for treating triquetral body fractures are less clear. Displaced fractures will likely require open reduction and internal fixation. Concomitant intercarpal ligamentous injuries, such as those to the lunotriquetral ligament, may be associated with such fractures and need operative repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for surgical referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are re-examined out of the cast every two to three weeks. Typically a dorsal avulsion fracture will only need two to four weeks of immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ] whereas a body fracture often requires four to six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36723/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. X-rays should be repeated every two to three weeks. Small avulsion fractures may not need a follow-up x-ray if progressing well clinically. Some patients may experience mild discomfort over the dorsum of the wrist for several months. If the patient remains symptomatic from a dorsal avulsion fracture, excision of the fragment may be needed and the patient should be referred. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for surgical referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503784\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the scaphoid and capitate, there is little risk of avascular necrosis of the triquetrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient can continue with work or sports while in the cast. If the patient is an athlete or heavy laborer, a padded cast provides sufficient protection. In the case of avulsion fractures, athletes may return to participation when pain does not interfere with activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dorsal avulsion fractures of the triquetrum are common. Patients typically present with a history of injury and pain at the ulnar aspect of the wrist. Examination reveals tenderness either dorsally or on the ulnar border of the wrist. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body fractures of the triquetrum are generally found on an AP wrist radiograph, while avulsion fractures are typically seen on lateral views. Additional views may be needed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chip and avulsion fractures are treated symptomatically and generally heal well with cast immobilization for two to four weeks. Body fractures require a short arm cast for four to six weeks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike the scaphoid and capitate, there is little chance of avascular necrosis of the triquetrum.",
"     </li>",
"     <li>",
"      Continued wrist pain despite radiographic healing suggests a possible concomitant injury to the triangular fibrocartilage complex or an undiagnosed ligamentous disruption and warrants further imaging and evaluation by a hand surgeon. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Avulsion fracture fragments that remain symptomatic despite appropriate conservative care may need excision and referral to a hand surgeon is prudent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059952\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckenbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE.  (Ed), Williams &amp; Wilkins, Philadelphia 1982.",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL, Calmbach WL. Carpal fractures. In: Fracture Management for Primary Care, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36723/abstract/3\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36723/abstract/4\">",
"      H&ouml;cker K, Menschik A. Chip fractures of the triquetrum. Mechanism, classification and results. J Hand Surg Br 1994; 19:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36723/abstract/5\">",
"      Marchessault J, Conti M, Baratz ME. Carpal fractures in athletes excluding the scaphoid. Hand Clin 2009; 25:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36723/abstract/6\">",
"      Papp S. Carpal bone fractures. Orthop Clin North Am 2007; 38:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36723/abstract/7\">",
"      Smith DK, Murray PM. Avulsion fractures of the volar aspect of triquetral bone of the wrist: a subtle sign of carpal ligament injury. AJR Am J Roentgenol 1996; 166:609.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH Jr, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fracutres in Adults, 5th, Bucholz RW, Heckman JD.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36723/abstract/9\">",
"      Papp S. Carpal bone fractures. Hand Clin 2010; 26:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 199 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.231-DF96EE1385-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36723=[""].join("\n");
var outline_f35_55_36723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1503784\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1059952\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/199|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?5/53/5983\" title=\"diagnostic image 2A\">",
"      Triquetral fracture difficulty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/31/31230\" title=\"diagnostic image 2B\">",
"      Triquetral fracture lateral xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/6/44142\" title=\"diagnostic image 2C\">",
"      Triquetral fracture oblique xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/199|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/31/1527\" title=\"figure 1\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/15/43263\" title=\"figure 2\">",
"      Volar forearm splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/45/14039?source=related_link\">",
"      Anatomy and basic biomechanics of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/21/12632?source=related_link\">",
"      Evaluation of the adult with acute wrist pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_55_36724="Pyoderma faciale";
var content_f35_55_36724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyoderma faciale (rosacea fulminans)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intensely inflammatory large plaque with pustules and sinus tracts is present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36724=[""].join("\n");
var outline_f35_55_36724=null;
var title_f35_55_36725="Pancreatitis extending to the root of the mesentery";
var content_f35_55_36725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Pancreatitis extending to the root of the mesentery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that there is inflammatory change with edema extending to the mesenteric root.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Pierre Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36725=[""].join("\n");
var outline_f35_55_36725=null;
var title_f35_55_36726="Medication positions PI";
var content_f35_55_36726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Positions for administering sinus medications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These positions allow nasal medications to penetrate into the sinuses, highlighted in green in the right-hand column. To give the medications, get into the position shown and give the medication into the nose. Stay in the position for the amount of time specified by your healthcare provider. For the maxillary sinuses (first position), the medication must be given on each side separately. For the other two positions, medications can be given to both sides of the nose at the same time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel L Hamilos, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36726=[""].join("\n");
var outline_f35_55_36726=null;
var title_f35_55_36727="Chronic paronychia 1";
var content_f35_55_36727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53529%7EDERM%2F63272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53529%7EDERM%2F63272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic paronychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic paronychia. Note the swelling of the proximal nail fold, the loss of the cuticle, and the dystrophy of the nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic paronychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the swelling of the proximal nail fold, the loss of the cuticle, and the dystrophy of the nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36727=[""].join("\n");
var outline_f35_55_36727=null;
var title_f35_55_36728="Definition, risk factors, and evaluation of resistant hypertension";
var content_f35_55_36728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition, risk factors, and evaluation of resistant hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     David A Calhoun, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36728/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/55/36728/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hypertension despite multiple medications are at high risk for adverse cardiovascular events and are more likely than those with controlled hypertension to have a secondary (ie, identifiable) cause, which is usually at least in part reversible.",
"   </p>",
"   <p>",
"    The definition, prevalence, risk factors and evaluation of resistant hypertension will be reviewed here. Specific causes of secondary hypertension will be briefly mentioned. The treatment and prognosis of resistant hypertension, indications for referral to a hypertension specialist, and how one identifies patients who should be screened for secondary hypertension are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=see_link\">",
"     \"Treatment of resistant hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Resistant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant hypertension is defined in the 2008 American Heart Association scientific statement as blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, patients whose blood pressure is controlled with four or more medications should be considered to have resistant hypertension.",
"   </p>",
"   <p>",
"    If tolerated, one of the three agents should be a diuretic and all agents should be prescribed at optimal doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/1\">",
"     1",
"    </a>",
"    ]. Goal blood pressure is less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg in average risk hypertensive patients. There is evidence supporting a lower goal blood pressure in patients with atherosclerotic cardiovascular disease, diabetes mellitus, or chronic kidney disease. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with resistant hypertension may have elevations in both systolic and diastolic pressures, isolated systolic hypertension is common. In the ALLHAT trial of over 33,000 hypertensive patients treated with different antihypertensive drugs, only 67 percent of participants attained a systolic blood pressure below 140 mmHg, whereas 92 percent attained a diastolic pressure below 90 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistant hypertension is",
"    <strong>",
"     not",
"    </strong>",
"    synonymous with uncontrolled hypertension since resistant hypertension is not the only cause of uncontrolled hypertension. Other causes include inadequate treatment regimens and pseudoresistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2761182\">",
"    <span class=\"h3\">",
"     Refractory hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with resistant hypertension cannot be controlled, even with maximal medical therapy (four or more drugs with complementary mechanisms given at maximal tolerated doses) under the care of a hypertension specialist. Such patients are referred to as having",
"    <strong>",
"     refractory hypertension",
"    </strong>",
"    . The prevalence and characteristics of refractory hypertension were evaluated in a cohort of 304 patients referred to a specialized hypertension clinic for management of resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/3\">",
"     3",
"    </a>",
"    ]. Refractory hypertension was defined as the inability to achieve blood pressure control (to less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg) despite at least three visits to the hypertension clinic over six or more months. The patients with refractory hypertension (approximately 10 percent of those referred for resistant hypertension) achieved a mean blood pressure of",
"    <span class=\"nowrap\">",
"     168/94",
"    </span>",
"    mmHg despite an average of seven hypertension clinic visits over a mean of eleven months and the use of six antihypertensive medications. Compared with patients who had controlled resistant hypertension, those with refractory hypertension had significantly higher heart rates (81 versus 70 beats per minute, despite more beta-blocker use), and diminished responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    therapy (13 versus 24 mmHg reduction in systolic pressure). Patients with and without refractory hypertension were otherwise similar.",
"   </p>",
"   <p>",
"    Based upon the persistently higher heart rates and lack of response to intensive diuretic therapy among patients with refractory hypertension, the authors suggested that treatment failure in such patients may be due to neurologic mechanisms (eg, sympathetic overactivity). This contrasts with the conventional thinking that resistant hypertension is largely due to persistent hypervolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pseudoresistant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudoresistance refers to poorly controlled hypertension that appears resistant to treatment but is actually attributable to other factors. The three most common causes of pseudoresistance are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inaccurate measurement of blood pressure (eg, use of an inappropriately small blood pressure cuff). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"       \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor adherence to antihypertensive therapy. In one study, for example, 40 out of 76 patients with unexplained resistance to four or more antihypertensive drugs were determined to be either nonadherent or only partially adherent to therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=see_link\">",
"       \"Patient adherence and the treatment of hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      White coat hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     White coat hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;White coat hypertension (also called isolated clinic or office hypertension) refers to patients who have office readings that average more than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg and",
"    <strong>",
"     reliable",
"    </strong>",
"    out of office readings that average less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. Having the BP in the office taken by a nurse or technician, rather than the physician, may minimize the white coat effect (",
"    <a class=\"graphic graphic_figure graphicRef73781 \" href=\"mobipreview.htm?24/2/24621\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    White coat hypertension is present in as many as 20 to 30 percent of patients, possibly leading to an erroneous diagnosis of either hypertension or, in a patient with known hypertension, resistant disease. It is more common among patients with resistant hypertension, with a reported prevalence of 37 to 44 percent in four studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with white coat hypertension have less severe target organ damage and appear to be at less cardiovascular risk compared to those patients with persistent hypertension during ambulatory monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/5-7,9\">",
"     5-7,9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ambulatory and home BP monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The true prevalence of resistant hypertension is not known. A major problem is that not all patients with uncontrolled hypertension have resistant hypertension as defined above; many are uncontrolled because of poor adherence or inadequate treatment regimens. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Resistant hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In an unselected, population based sample of 15,968 adults in the United States, the prevalence of resistant hypertension was 8.9 percent among all individuals with hypertension, and 12.8 percent among those treated with antihypertensive medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/10\">",
"     10",
"    </a>",
"    ]. In selected populations of hypertensive patients who seek medical care, the prevalence may be higher, ranging from 12.3 percent in Spain to 16 percent in the southeastern United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/5,10-12\">",
"     5,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of antihypertensive medication prescriptions written in the United States suggested that the prevalence of more difficult to control hypertension is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/13\">",
"     13",
"    </a>",
"    ]. The proportion of hypertensive patients receiving three or more blood pressure medications increased from 14 to 24 percent between 1994 and 2004. Possible reasons for the increase in difficult to control hypertension include increases in the average age and the average weight of the population. Data were not given on resistant hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient characteristics that predict difficult to control hypertension include higher baseline blood pressure (particularly systolic), presence of left ventricular hypertrophy, older age, obesity, African American race, chronic kidney disease, and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potentially reversible factors that contribute to resistant hypertension include suboptimal therapy, lifestyle and diet, medications and herbal preparations that can raise the blood pressure, and secondary causes of hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Suboptimal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suboptimal therapy is a common cause of resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/1\">",
"     1",
"    </a>",
"    ]. It is most often due to the lack of administration of more effective drugs and failure to prevent volume expansion with adequate diuretic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Extracellular volume expansion'",
"    </a>",
"    below.) In one report, only 18 and 27 percent of patients with uncontrolled hypertension were treated with at least three antihypertensive drugs (one of which being a diuretic) by general practitioners and cardiologists, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lifestyle and diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity, a high salt diet, physical inactivity, and heavy alcohol intake all contribute to hypertension, although not all have been examined specifically among patients with resistant hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2998?source=see_link\">",
"     \"Exercise in the treatment and prevention of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The contribution of dietary salt to resistant hypertension was examined in a randomized trial in which twelve patients with resistant hypertension were assigned to low (50",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    or high (250",
"    <span class=\"nowrap\">",
"     meq/day)",
"    </span>",
"    sodium diet for one week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/17\">",
"     17",
"    </a>",
"    ]. After a two-week washout, the patients received the other diet. Switching from the high to low salt diet was associated with an average reduction in office blood pressure of",
"    <span class=\"nowrap\">",
"     23/9",
"    </span>",
"    mmHg, and a reduction in the 24-hour ambulatory blood pressure of",
"    <span class=\"nowrap\">",
"     20/10",
"    </span>",
"    mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of medications can raise the BP and, in some cases, reduce the response to antihypertensive drugs. The most commonly implicated agents are over-the-counter and prescribed medications including nonsteroidal antiinflammatory drugs (NSAIDs), including some but not all (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    ) of the selective cyclooxygenase-2 (COX-2) inhibitors (",
"    <a class=\"graphic graphic_table graphicRef56767 \" href=\"mobipreview.htm?14/40/14987\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=see_link&amp;anchor=H9#H9\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NSAIDs that raise blood pressure can interfere with the antihypertensive effect of virtually any agent, except calcium channel blockers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/16\">",
"     16",
"    </a>",
"    ]. A presumed mechanism by which the blood pressure rises is a reduction in sodium excretion, thereby increasing the intravascular volume. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other agents that may contribute to hypertension include sympathomimetics (diet pills, decongestants, amphetamine-like stimulants), glucocorticoids, herbal preparations, estrogen-containing contraceptives, calcineurin inhibitors, and antidepressants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=see_link\">",
"     \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Extracellular volume expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative or absolute volume expansion is frequently at least partially responsible for an inability to control hypertension BP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Underlying renal insufficiency, sodium retention due to therapy with vasodilators,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ingestion of a high salt diet (which can be assessed by measuring sodium excretion in a 24-hour urine collection) all may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Secondary causes of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with resistant hypertension are much more likely to have an identifiable cause of hypertension (ie, secondary hypertension) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/1,20,24\">",
"     1,20,24",
"    </a>",
"    ]. The most common are primary aldosteronism and renal artery stenosis, chronic kidney disease, and obstructive sleep apnea (",
"    <a class=\"graphic graphic_table graphicRef77787 \" href=\"mobipreview.htm?12/21/12635\">",
"     table 2",
"    </a>",
"    ). Less common causes include pheochromocytoma, Cushing's syndrome, and aortic coarctation.",
"   </p>",
"   <p>",
"    All of these disorders are reviewed in detail elsewhere on the appropriate topic reviews. The following discussion will be limited to their association with resistant hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical clues suggesting the possible presence of secondary rather than essential hypertension, one of which is resistant hypertension. Thus, secondary hypertension should be considered in all patients with resistant hypertension. The clinical clues suggesting secondary hypertension are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Primary aldosteronism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary aldosteronism has been reported in approximately 10 to 20 percent of patients with resistant hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Otherwise unexplained hypokalemia is the major clue to the presence of primary hyperaldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/26\">",
"     26",
"    </a>",
"    ]. However, more than 50 percent of patients with proven primary hyperaldosteronism are normokalemic at presentation. Thus, the absence of hypokalemia does not exclude this disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Variable presentation of primary aldosteronism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest published experience of 1616 patients with resistant hypertension, 11 percent fulfilled criteria for primary aldosteronism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/25\">",
"     25",
"    </a>",
"    ]. Among the patients with primary aldosteronism, only 46 percent had hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Renal artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal artery stenosis is a common cause of resistant hypertension and can be due to either atherosclerotic disease or, in younger patients, fibromuscular dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34471?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As renal function declines in patients with chronic kidney disease, there is an increasing need for additional antihypertensive medications. Diuretics play a central role. Diuretics should be pushed until the blood pressure goal is reached or the patient has attained \"dry weight\" which, in the presence of persistent hypertension, is defined as the weight at which further fluid loss leads to either symptoms (fatigue, orthostatic hypotension) or decreased tissue perfusion as evidenced by an otherwise unexplained elevation in the blood urea nitrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum creatinine concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of hypertension in acute and chronic kidney disease\", section on 'Choice of antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Obstructive sleep apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea is common among patients with resistant hypertension who are referred for sleep studies. In three series of patients with resistant hypertension who were referred for sleep studies, significant obstructive sleep apnea was detected in 71 to 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/28-30\">",
"     28-30",
"    </a>",
"    ] and, in one, was significantly more common than in patients with controlled hypertension (71 versus 38 percent, adjusted odds ratio 4.8, 95% CI 2.0-11.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/28\">",
"     28",
"    </a>",
"    ]. The severity of sleep apnea correlates with the severity of hypertension and both the incidence and severity of sleep apnea were greater in men than women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon such observations, we suggest screening for obstructive sleep apnea in patients with resistant hypertension who have one or more of the following risk factors: obesity, loud snoring,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    daytime sleepiness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of obstructive sleep apnea with positive airway pressure provides a usually modest antihypertensive benefit among patients with hypertension. The effect in resistant hypertension has not been well studied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Systemic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BLOOD PRESSURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of resistant hypertension depends upon an accurate measurement of the blood pressure. To avoid falsely high readings, it is particularly important to have the patient sit quietly for three to five minutes before taking the measurement, to use the correct cuff size (the adult large cuff for the majority of patients with resistant hypertension), and to support the arm at heart level during measurement. The blood pressure should be measured in both arms, with the arm with the higher pressure being used to make future measurements.",
"   </p>",
"   <p>",
"    These and other components of blood pressure measurement are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ambulatory and home BP monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, some patients have pseudoresistant hypertension due to errors in blood pressure (BP) measurement or white coat hypertension. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pseudoresistant hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical findings that should raise suspicion of white coat hypertension include poorly-controlled office hypertension without evidence of end-organ damage (such as left ventricular hypertrophy on an echocardiogram) or symptoms suggestive of hypoperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/31\">",
"     31",
"    </a>",
"    ]. On the other hand, true resistant hypertension is likely when the office systolic pressure is &ge;180 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient has echocardiographic or electrocardiographic evidence of left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resistant hypertension can only be distinguished from white coat hypertension by out-of office blood pressure measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/6\">",
"     6",
"    </a>",
"    ]. This is best accomplished with 24-hour ambulatory monitoring, although home and workplace assessments can be utilized if one is confident that the blood pressure is being measured accurately. We believe that ambulatory measurements should ideally be attained in all patients with resistant hypertension.",
"   </p>",
"   <p>",
"    If out-of-office readings are at or below the desired target, while office readings remain elevated, home or office readings may be used to guide medication adjustments. In addition to out-of-office measurements, the acute increase in office blood pressure can be minimized by having a nurse or technician take the blood pressure rather than the doctor (",
"    <a class=\"graphic graphic_figure graphicRef73781 \" href=\"mobipreview.htm?24/2/24621\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ambulatory monitoring is also a better predictor than office blood pressure measurements of cardiovascular morbidity (ie, end-organ damage) and mortality in patients with resistant hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of resistant hypertension\", section on 'Out-of-office BP monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cuff inflation hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible problem with self-measurement using a sphygmomanometer is that the muscular activity used to inflate the cuff can acutely raise the BP by as much as",
"    <span class=\"nowrap\">",
"     12/9",
"    </span>",
"    mmHg, an effect called cuff inflation hypertension that dissipates within 5 to 20 seconds (average 7 seconds in one study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, inflating the cuff to at least 30 mmHg above systolic and then allowing the sphygmomanometer to fall no more than 2 to 3 mmHg per heartbeat is desirable both for accurate measurement and to permit this exertional to disappear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/31\">",
"     31",
"    </a>",
"    ]. This problem can be avoided with automated home blood pressure devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OTHER COMPONENTS OF EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients with suspected resistant hypertension should confirm true treatment resistance, identify contributing factors including secondary causes of hypertension, and document target-organ damage including retinopathy, left ventricular hypertrophy, and kidney disease (",
"    <a class=\"graphic graphic_algorithm graphicRef75093 \" href=\"mobipreview.htm?20/33/21011\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pseudoresistance is excluded by an assessment of treatment adherence and the accurate determination of blood pressure. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pseudoresistant hypertension'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medical history should document age of onset, duration, severity, and progression of the hypertension. Current medication use (including herbal and over-the-counter medications) and the response to prior medications should be determined. Patient adherence is established mostly by self-report. The clinician should ask about adverse effects of medications, out-of-pocket costs, and dosing inconvenience, all of which can limit adherence.",
"   </p>",
"   <p>",
"    The patient should also be questioned about possible manifestations of secondary causes of hypertension, such as pheochromocytoma and Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include careful measurement of the blood pressure and fundoscopic examination looking for retinopathy. In addition, signs that suggest secondary causes of hypertension may be present. As examples, carotid, abdominal, or femoral bruits suggest atherosclerotic disease and possible renal artery stenosis, diminished femoral pulses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a discrepancy between arm and thigh blood pressures suggest aortic coarctation or significant aortoiliac disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link&amp;anchor=H1088178828#H1088178828\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Blood pressure and pulses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing in patients with resistant hypertension includes measurement of serum electrolytes, glucose, and creatinine, and a urinalysis with estimation of proteinuria (eg, urine albumin-to-creatinine ratio).",
"   </p>",
"   <p>",
"    Screening for primary aldosteronism is also warranted since, in the largest published experience of 1616 patients with resistant hypertension, 11 percent fulfilled criteria for primary aldosteronism, only 46 percent of whom were hypokalemic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36728/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Primary aldosteronism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Screening for primary aldosteronism begins with a paired, morning measurement of the plasma aldosterone concentration (PAC) and plasma renin activity (PRA) to determine whether the patient has an elevated or high normal PAC, suppressed PRA, and elevated",
"    <span class=\"nowrap\">",
"     PAC/PRA",
"    </span>",
"    ratio. Certain antihypertensive drugs can alter the ratio, some of which should be discontinued prior to testing. If the ratio suggests primary aldosteronism, further evaluation is necessary to confirm the diagnosis. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Plasma aldosterone to renin ratio'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the patient with hypertension and hypokalemia\", section on 'Protocol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to blood testing, a 24-hour urine collection should be obtained on the patient's usual diet for determination of sodium excretion, creatinine clearance, and aldosterone excretion. Urinary sodium excretion permits estimation of dietary sodium intake unless the patient has been recently (within the past two weeks) started on a diuretic or there has been a recent dose increase.",
"   </p>",
"   <p>",
"    Patients with resistant hypertension should be evaluated for pheochromocytoma if they have suggestive manifestations such as episodic hypertension, palpitations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diaphoresis, or tremor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Noninvasive imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with resistant hypertension should undergo noninvasive imaging for renal artery stenosis. This is particularly important in patients with known atherosclerotic disease in other vascular beds, including peripheral artery disease, coronary artery disease or cerebrovascular disease, an abdominal bruit, a rise in serum creatinine after initiation of an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, or, onset of hypertension at a young age which could represent fibromuscular dysplasia.",
"   </p>",
"   <p>",
"    Among patients with resistant hypertension who have none of these risk factors, we delay screening for renovascular disease until the remainder of the evaluation for resistant hypertension is negative. The preferred methods of screening are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of low specificity, imaging studies should not be performed to screen for adrenal adenomas in the absence of biochemical evidence of hormonally active tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resistant hypertension is defined as blood pressure that remains above goal in spite of concurrent use of three antihypertensive agents of different classes, or blood pressure that is controlled with four or more medications. One of the medications should be a diuretic, if tolerated, and all should be prescribed at optimal dosages. About 10 percent of patients with resistant hypertension cannot be controlled (called refractory hypertension) despite maximal medical therapy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistant hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2761182\">",
"       'Refractory hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudoresistant hypertension refers to hypertension resulting from inaccurate measurement of blood pressure (eg, use of an inappropriately small blood pressure cuff), poor adherence to antihypertensive therapy, or white coat hypertension. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pseudoresistant hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful blood pressure measurement technique is essential to establish an accurate diagnosis of resistant hypertension. Out-of-office blood pressure measurements, including 24-hour ambulatory monitoring, may be required to exclude white coat hypertension. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Blood pressure measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potentially reversible factors that contribute to resistant hypertension include suboptimal therapy, lifestyle and diet, medications and herbal preparations that can raise the blood pressure, and secondary causes of hypertension. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with resistant hypertension should be evaluated for the possible presence of primary aldosteronism, renal artery stenosis, chronic kidney disease, and obstructive sleep apnea. Less common identifiable causes of resistant hypertension include pheochromocytoma, Cushing's syndrome, and aortic coarctation. Screening for one of these disorders should only be performed if the patient has suggestive manifestations. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Secondary causes of hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation should include measurement of serum electrolytes, glucose, urea nitrogen and creatinine, and a urinalysis. A paired, morning plasma aldosterone concentration and plasma renin activity (PRA) should be measured to screen for primary aldosteronism. A 24-hour urine should be obtained for determination of sodium excretion, creatinine clearance, and aldosterone excretion. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/1\">",
"      Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/2\">",
"      Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/3\">",
"      Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/4\">",
"      Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/5\">",
"      de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/6\">",
"      Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/7\">",
"      Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/8\">",
"      de la Sierra A, Banegas JR, Oliveras A, et al. Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. J Hypertens 2012; 30:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/9\">",
"      Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/10\">",
"      Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076.",
"     </a>",
"    </li>",
"    <li>",
"     Egan, BM, Zhao, Y, Rehman, SU, et al. Treatment resistant hypertension in a community-based practice network. J Clin Hypertens 2009; OR-12:A6 (abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/12\">",
"      Muxfeldt ES, Nogueira Ada R, Salles GF, Bloch KV. Demographic and clinical characteristics of hypertensive patients in the internal medicine outpatient clinic of a university hospital in Rio de Janeiro. Sao Paulo Med J 2004; 122:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/13\">",
"      Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006; 48:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/14\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/15\">",
"      Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/16\">",
"      Amar J, Chamontin B, Genes N, et al. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003; 21:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/17\">",
"      Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/18\">",
"      Chan CC, Reid CM, Aw TJ, et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/19\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/20\">",
"      Setaro JF, Black HR. Refractory hypertension. N Engl J Med 1992; 327:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/21\">",
"      Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/22\">",
"      Licht CM, de Geus EJ, Seldenrijk A, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009; 53:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/23\">",
"      Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/24\">",
"      Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002; 39:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/25\">",
"      Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/26\">",
"      Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/27\">",
"      Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/28\">",
"      Gon&ccedil;alves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest 2007; 132:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/29\">",
"      Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/30\">",
"      Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/31\">",
"      Mejia AD, Egan BM, Schork NJ, Zweifler AJ. Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med 1990; 112:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36728/abstract/32\">",
"      Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3818 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-46EA05C0BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36728=[""].join("\n");
var outline_f35_55_36728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2761182\">",
"      - Refractory hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pseudoresistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - White coat hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Suboptimal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lifestyle and diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Extracellular volume expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Secondary causes of hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical clues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BLOOD PRESSURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ambulatory and home BP monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cuff inflation hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OTHER COMPONENTS OF EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Noninvasive imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3818|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?20/33/21011\" title=\"algorithm 1\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3818|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/2/24621\" title=\"figure 1\">",
"      BP by doctor and nurse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3818|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/40/14987\" title=\"table 1\">",
"      Agents that increase BP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/21/12635\" title=\"table 2\">",
"      Secondary causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/42/34471?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromuscular dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/2998?source=related_link\">",
"      Exercise in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23828?source=related_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35256?source=related_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_55_36729="Cyclosporine (systemic): Pediatric drug information";
var content_f35_55_36729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclosporine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30858?source=see_link\">",
"    see \"Cyclosporine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=see_link\">",
"    see \"Cyclosporine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F8012536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gengraf&reg;;",
"     </li>",
"     <li>",
"      Neoral&reg;;",
"     </li>",
"     <li>",
"      SandIMMUNE&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8012540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cyclosporine&reg;;",
"     </li>",
"     <li>",
"      Neoral&reg;;",
"     </li>",
"     <li>",
"      Rhoxal-cyclosporine;",
"     </li>",
"     <li>",
"      Sandimmune&reg; I.V.;",
"     </li>",
"     <li>",
"      Sandoz-Cyclosporine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10825673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10825602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30858?source=see_link\">",
"      see \"Cyclosporine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults (oral dosage is ~3 times the I.V. dosage):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transplantations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Cyclosporine (non-modified):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 5-6 mg/kg/dose (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     the oral dose) administered 4-12 hours prior to organ transplantation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance: 2-10 mg/kg/day in divided doses every 8-24 hours; patients should be switched to oral cyclosporine as soon as possible; cyclosporine doses should be adjusted to maintain whole blood HPLC trough concentrations in the reference range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Cyclosporine (non-modified):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: 14-18 mg/kg/dose administered 4-12 hours prior to organ transplantation; lower initial doses of 10-14 mg/kg/day have been used for renal transplants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance, postoperative: 5-15 mg/kg/day divided every 12-24 hours; maintenance dose is usually tapered to 3-10 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     When using non-modified formulation, cyclosporine levels may increase in liver transplant patients when the T-tube is closed; may need to decrease dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: Cyclosporine (modified): Based on the organ transplant population:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial: Same as the initial dose for solution or soft gelatin capsule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Renal: 9 mg/kg/day (range: 6-12 mg/kg/day) divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Liver: 8 mg/kg/day (range: 4-12 mg/kg/day) divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Heart: 7 mg/kg/day (range: 4-10 mg/kg/day) divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A 1:1 ratio conversion from Sandimmune&reg; to Neoral&reg; has been recommended initially; however, lower doses of Neoral&reg; may be required after conversion to prevent overdose. Total daily doses should be adjusted based on the cyclosporine trough blood concentration and clinical assessment of organ rejection. Cyclosporine blood trough levels should be determined prior to conversion. After conversion to Neoral&reg;, cyclosporine trough levels should be monitored every 4-7 days.",
"     <b>",
"      Neoral&reg; and Sandimmune&reg; are not bioequivalent and cannot be used interchangeably.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Focal segmental glomerulosclerosis: Oral: Initial: 3 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rheumatoid arthritis: Oral: Cyclosporine (modified): Initial: 2.5 mg/kg/day divided every 12 hours; may increase dose by 0.5-0.75 mg/kg/day if insufficient response is seen after 8 weeks of treatment; maximum dose: 4 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Psoriasis: Oral: Cyclosporine (modified): Initial: 2.5 mg/kg/day divided every 12 hours; may increase dose by 0.5 mg/kg/day if insufficient response is seen after 4 weeks of treatment; maximum dose: 4 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Autoimmune diseases: Oral: 1-3 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [modified]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gengraf&reg;: 25 mg, 100 mg [contains ethanol 12.8%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [non-modified]: 25 mg [DSC], 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral [modified]: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neoral&reg;: 25 mg, 100 mg [contains corn oil, dehydrated ethanol 11.9%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral [non-modified]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SandIMMUNE&reg;: 25 mg, 100 mg [contains corn oil, dehydrated ethanol 12.7%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [non-modified]: 50 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SandIMMUNE&reg;: 50 mg/mL (5 mL) [contains ethanol 32.9%, polyoxyethylated castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [modified]: 100 mg/mL (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gengraf&reg;: 100 mg/mL (50 mL) [contains propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neoral&reg;: 100 mg/mL (50 mL) [contains corn oil, dehydrated ethanol 11.9%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [non-modified]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SandIMMUNE&reg;: 100 mg/mL (50 mL) [contains ethanol 12.5%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8012552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes non-modified solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10825603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer consistently at the same time twice daily; use oral syringe, glass dropper, or glass container (not plastic or styrofoam cup); to improve palatability, oral solution may be mixed with milk, chocolate milk, orange juice, or apple juice that is at room temperature; dilution of Neoral&reg; with milk can be unpalatable; stir well and drink at once; do not allow to stand before drinking; rinse with more diluent to ensure that the total dose is taken; after use, dry outside of glass dropper; do not rinse with water or other cleaning agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: May administer by I.V. intermittent infusion or continuous infusion; for intermittent infusion, administer over 2-6 hours at a final concentration not to exceed 2.5 mg/mL. Anaphylaxis has been reported with I.V. use. Patients should be continuously monitored for at least the first 30 minutes of the infusion and should be monitored frequently thereafter",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8012567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, fat emulsion 10%, fat emulsion 20%, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ampicillin,  anidulafungin, caspofungin, cefazolin, cefotaxime, cefoxitin, cefuroxime, chloramphenicol, ciprofloxacin, clindamycin, doripenem, doxyclycine, erythromycin lactobionate, gentamicin, kanamycin, linezolid, meropenem, metronidazole, micafungin, minocycline, nafcillin, oxacillin, penicillin G potassium, piperacillin, propofol, sargramostim, sulfamethoxazole/trimethoprim, ticarcillin/clavulanic acid, tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B cholesteryl sulfate complex, drotrecogin alfa, mycophenolate, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dopamine, magnesium sulfate, ondansetron, telavancin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10825600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not store oral solution or oral solution for emulsion in the refrigerator; store oral solutions in original container only and use contents within 2 months after opening; store ampuls and ophthalmic emulsion-containing vials at room temperature; protect from light; I.V. cyclosporine prepared in NS is stable 6 hours in a polyvinyl chloride container or 12 hours in a glass container; I.V. cyclosporine diluted in D",
"     <sub>",
"      5",
"     </sub>",
"     W to a final concentration of 2 mg/mL is stable for 24 hours in glass or polyvinyl chloride containers; I.V. cyclosporine may bind to the plastic tubing in I.V. administration sets and to polyvinyl chloride bags. Polyoxyethylated castor oil (Cremophor El&reg;) surfactant in cyclosporine injection may leach phthalate from polyvinyl chloride containers, such as bags and tubing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10825674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunosuppressant used with corticosteroids to prevent organ rejection in patients with kidney, liver, lung, heart, and bone marrow transplants; treatment of nephrotic syndrome in patients with documented focal glomerulosclerosis when corticosteroids and cyclophosphamide are unsuccessful; severe psoriasis; severe rheumatoid arthritis not responsive to methotrexate alone; severe autoimmune disease that is resistant to corticosteroids and other therapy; prevention and treatment of graft-versus-host disease in bone marrow transplant patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8012538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CycloSPORINE may be confused with cyclophosphamide, Cyklokapron&reg;, cycloSERINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CycloSPORINE modified (Neoral&reg;, Gengraf&reg;) may be confused with cycloSPORINE non-modified (SandIMMUNE&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gengraf&reg; may be confused with Prograf&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Neoral&reg; may be confused with Neurontin&reg;, Nizoral&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SandIMMUNE&reg; may be confused with SandoSTATIN&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8012604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Abnormal heart sounds, arrhythmia, cardiac failure, chest pain, edema, glomerular capillary thrombosis, hypertension, MI, peripheral ischemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, convulsions, depression, dizziness, emotional lability, fever, headache, hypoesthesia, impaired concentration, insomnia, lethargy, malaise, migraine, nervousness, pain, paranoia, psychiatric events, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Abnormal pigmentation, acne, angioedema, brittle fingernails, cellulitis, dermatitis, dry skin, eczema, folliculitis, hair breaking, hirsutism, hypertrichosis, keratosis, purpura, pruritus, rash, skin disorder, skin malignancies, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: breast fibroadenosis, breast pain, diabetes mellitus, female reproductive disorder, goiter, gynecomastia, hot flashes, hyper-/hypoglycemia, hyperkalemia, hyperuricemia, hypomagnesemia, libido increased/decreased, menstrual disorder, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, anorexia, constipation, cramps, dry mouth, diarrhea, dyspepsia, dysphagia, enanthema, eructation, esophagitis, flatulence, gastric ulcer, gastritis, gastroenteritis, gastrointestinal bleeding (upper), gingival bleeding, gingivitis, glossitis, gum hyperplasia, mouth sores, nausea, pancreatitis, peptic ulcer, salivary gland enlargement, swallowing difficulty, taste perversion, tongue disorder, gum hyperplasia, vomiting, weight loss/gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Abnormal urine, leukorrhea, micturition increased, micturition urgency, nocturia, polyuria, pyelonephritis, urinary incontinence, uterine hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding disorder, clotting disorder, leukopenia, platelet disorder, red blood cell disorder, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, bone fracture, joint dislocation, joint pain, leg cramps/muscle contractions, muscle pain, myalgia, neuropathy, paresthesia, stiffness, synovial cyst, tendon disorder, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal vision, cataract, conjunctivitis, eye pain, visual disturbance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Deafness, hearing loss, tinnitus, vestibular disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, hematuria, renal abscess, renal dysfunction/nephropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Abnormal chest sounds, bronchospasm, cough, dyspnea, epistaxis, pharyngitis, pneumonia, respiratory infection, rhinitis, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abscess, allergic reactions, bacterial infection, carcinoma, diaphoresis increased, Flu-like syndrome, fungal infection, herpes simplex, herpes zoster, hiccups, infection, lymphadenopathy, lymphoma, moniliasis, night sweats, tonsillitis, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Anaphylaxis/anaphylactoid reaction (possibly associated with Cremophor&reg; EL vehicle in injection formulation), benign intracranial hypertension, cholesterol increased, death (due to renal deterioration), encephalopathy, gout, hyperbilirubinemia, hyperkalemia, impaired consciousness, infections (increased risk; including JC virus and BK virus), migraine headache, neurotoxicity, papilloedema, polyoma virus-associated nephropathy (PVAN), progressive multifocal leukoencephalopathy (PML), pulmonary edema (noncardiogenic), reversible posterior leukoencephalopathy syndrome (RPLS), thrombotic microangiopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10825675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclosporine or any component (ie, polyoxyl 35 castor oil is an ingredient of the parenteral formulation and polyoxyl 40 hydrogenated castor oil is an ingredient of the cyclosporine capsules and solution for microemulsion). AAP considers cyclosporine to be contraindicated during breast-feeding. Concurrent therapy with PUVA or UVB, methotrexate, coal tar, or radiation therapy for use in patients with psoriasis; presence of uncontrolled hypertension, abnormal renal function, or malignancies in treatment of psoriasis or rheumatoid arthritis.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10825596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Close monitoring and dosage adjustment is required in patients with renal and hepatic impairment. Cyclosporine (modified) has increased bioavailability as compared to cyclosporine (non-modified) and cannot be used interchangeably without close monitoring",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use caution when changing dosage forms since products cannot be used interchangeably. Should only be prescribed by physicians experienced in the management of systemic immunosuppressants",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10825676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Immunosuppression with cyclosporine may result in an increased susceptibility to infection",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; fatal infections have been reported. May increase the risk of malignancy (lymphomas, lymphoproliferative disorders, and squamous cell carcinoma)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; closely monitor and be prepared to treat anaphylaxis in patients receiving I.V. cyclosporine. Renal impairment, including structural kidney damage, has occurred (when used at high doses)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; serious nephrotoxicity, hepatotoxicity, hypertension, and/or seizures may occur in children receiving cyclosporine;",
"     <b>",
"      monitor renal function and adjust dosage to avoid toxicity or possible organ rejection via cyclosporine blood or plasma concentration monitoring.",
"     </b>",
"     Use caution when using with other nephrotoxic drugs. Immunosuppressed patients are at increased risk for opportunistic infections (eg, activation of latent viral infection, including BK virus-associated nephropathy, which may impair renal function and cause graft loss). Consider decreasing immunosuppressive burden if renal function deteriorates and BK nephropathy is suspected.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Transplant patients: Cyclosporine may cause significant hyperkalemia and hyperuricemia. May cause seizures, particularly if used with high-dose corticosteroids. Predisposing factors associated with neurological disorders include hypertension, hypomagnesemia, hypocholesterolemia, high-dose corticosteroids, high cyclosporine serum concentration, and graft-versus-host disease. Risk of skin cancer may be increased in psoriasis patients with a history of PUVA and possibly methotrexate or other immunosuppressants, UVB, coal tar, or radiation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8012607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AcetaZOLAMIDE: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalimumab: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: CycloSPORINE (Systemic) may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ambrisentan: CycloSPORINE (Systemic) may increase the serum concentration of Ambrisentan.  Management: Limit ambrisentan dose to 5 mg/day and monitor for ambrisentan adverse reactions in patients receiving systemic cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Androgens: May enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: CycloSPORINE (Systemic) may increase the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Boceprevir. Management: Cyclosporine dose adjustments will likely be necessary when used together with boceprevir.  Monitor serum cyclosporine concentrations closely, and monitor patients for evidence of cyclosporine toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: CycloSPORINE (Systemic) may decrease the metabolism of Cardiac Glycosides.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin.  Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer cyclosporine at least 4 hours prior to colesevelam.  Monitor for decreased cyclosporine concentrations during concomitant colesevelam therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): CycloSPORINE (Systemic) may increase the serum concentration of Dexamethasone (Systemic). Dexamethasone (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: CycloSPORINE (Systemic) may increase the serum concentration of DOXOrubicin.  Management: Consider a doxorubicin dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution; increase monitoring for toxic effects of doxorubicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CycloSPORINE (Systemic) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: CycloSPORINE (Systemic) may decrease the metabolism of Etoposide.  Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: CycloSPORINE (Systemic) may increase the serum concentration of Etoposide Phosphate. CycloSPORINE may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CycloSPORINE (Systemic) may increase the serum concentration of Everolimus.  Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ezetimibe: CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: CycloSPORINE (Systemic) may diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of CycloSPORINE (Systemic). Management: Monitor for altered cyclosporine concentrations/effects if grapefruit intake is increased/decreased.  Advise patients to not alter their pattern of grapefruit/grapefruit juice intake without consulting their healthcare provider.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imipenem: CycloSPORINE (Systemic) may enhance the neurotoxic effect of Imipenem. Imipenem may increase the serum concentration of CycloSPORINE (Systemic). Imipenem may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CycloSPORINE (Systemic) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of CycloSPORINE (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melphalan: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: CycloSPORINE (Systemic) may increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CycloSPORINE (Systemic) may increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May increase the absorption of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May decrease the metabolism of Calcineurin Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CycloSPORINE (Systemic). Management: Avoid cyclosporine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minoxidil (Systemic): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minoxidil (Topical): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: CycloSPORINE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norfloxacin: May decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer orlistat at least 3 hours before or after oral cyclosporine.  Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic).  Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): CycloSPORINE (Systemic) may increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: CycloSPORINE (Systemic) may increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: CycloSPORINE (Systemic) may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyrazinamide: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinupristin: May increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: CycloSPORINE (Systemic) may increase the serum concentration of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Rosuvastatin.  Management: Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine.  Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED]. Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitaxentan: CycloSPORINE (Systemic) may increase the serum concentration of Sitaxentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Consider alternatives to St. John's wort (SJW). If the combination cannot be avoided, monitor for decreased cyclosporine concentrations/effects.  Monitor for increased cyclosporine concentrations/effects following SJW discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfinpyrazone [Off Market]: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): May enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the nephrotoxic effect of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Topical). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Significant cyclosporine dose reductions are likely to be required if used with telaprevir.  Concurrent use should be performed with great caution and close monitoring of both cyclosporine concentrations and clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10825599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grapefruit and grapefruit juice may affect cyclosporine metabolism, resulting in increased cyclosporine concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8012556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8012557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies (using doses that were not maternally toxic). In humans, cyclosporine crosses the placenta; maternal concentrations do not correlate with those found in the umbilical cord. Cyclosporine may be detected in the serum of newborns for several days after birth. Based on clinical use, premature births and low birth weight were consistently observed in pregnant transplant patients (additional pregnancy complications also present).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     A pregnancy registry has been established for pregnant women taking immunosuppressants following any solid organ transplant (National Transplantation Pregnancy Registry, Temple University, 877-955-6877).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     A pregnancy registry has also been established for pregnant women taking Neoral&reg; for psoriasis or rheumatoid arthritis (Neoral&reg; Pregnancy Registry for Psoriasis and Rheumatoid Arthritis, Thomas Jefferson University, 888-522-5581).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10825784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood/serum drug concentration (trough), blood drug concentration (C",
"     <sub>",
"      2",
"     </sub>",
"     ), renal and hepatic function tests, serum electrolytes, lipid profile, blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F10825785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reference ranges are method- and specimen-dependent; use the same analytical method consistently; trough levels should be obtained immediately prior to next dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic: Not well-defined; dependent on organ transplanted, time after transplant, organ function, and cyclosporine toxicity. Empiric therapeutic concentration ranges for trough cyclosporine concentrations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kidney: 100-200 ng/mL (serum, RIA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BMT: 100-250 ng/mL (serum, RIA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Heart: 100-200 ng/mL (serum, RIA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Liver: 100-400 ng/mL (blood, HPLC)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Method-dependent (optimum cyclosporine trough concentrations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serum, RIA: 150-300 ng/mL; 50-150 ng/mL (late post-transplant period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Whole blood, RIA: 250-800 ng/mL; 150-450 ng/mL (late post-transplant period)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Whole blood, HPLC: 100-500 ng/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     C",
"     <sub>",
"      2",
"     </sub>",
"     (cyclosporine concentration 2 hours after dose):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Blood, Fluorescence Polarization Immunoassay (FPIA): 1000-1500 ng/mL (in first 6 months after transplantation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Blood, FPIA: 800-900 ng/mL (in second 6 months after transplantation)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10825601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibition of production and release of interleukin II and inhibits interleukin II-induced activation of resting T lymphocytes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15836546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (nonmodified) solution or soft gelatin capsule: Erratically and incompletely absorbed; dependent on the presence of food, bile acids, and GI motility; larger oral doses of cyclosporine are needed in pediatric patients vs adults due to a shorter bowel length resulting in limited intestinal absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (modified) solution in a microemulsion or soft gelatin capsule in a microemulsion: Erratically and incompletely absorbed; increased absorption, up to 30% when compared to cyclosporine (nonmodified); absorption is less dependent on food intake, bile, or GI motility when compared to cyclosporine (nonmodified)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Widely distributed in tissues and body fluids including the liver, pancreas, and lungs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     V",
"     <sub>",
"      dss",
"     </sub>",
"     : 4-6 L/kg in renal, liver, and marrow transplant recipients (slightly lower values in cardiac transplant patients; children &lt;10 years of age have higher values)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 90% to 98% of dose binds to blood lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Undergoes extensive first-pass metabolism following oral administration; extensively metabolized by the cytochrome P450 system in the liver; forms at least 25 metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (nonmodified): Dependent on patient population and transplant type (&lt;10% in adult liver transplant patients and as high as 89% in renal patients). The bioavailability of Sandimmune&reg; capsules and oral solution are equivalent; bioavailability of oral solution is ~30% of the I.V. solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 28% (range: 17% to 42%); with gut dysfunction commonly seen in BMT recipients, oral bioavailability is further reduced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (modified): Bioavailability of Neoral&reg; capsules and oral solution are equivalent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 43% (range: 30% to 68%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 23% greater than with Sandimmune&reg; in renal transplant patients, 50% greater in liver transplant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: May be prolonged in patients with hepatic impairment and lower in pediatric patients due to a higher metabolic rate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (nonmodified): Biphasic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alpha phase: 1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Terminal phase: 6-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (modified): Biphasic; Terminal: 8.4 hours (range: 5-18 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (nonmodified): 2-6 hours; some patients have a second peak at 5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclosporine (modified): 1.5-2 hours (in renal transplant patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily biliary with 6% of the dose excreted in urine as unchanged drug (0.1%) and metabolites; clearance is more rapid in pediatric patients than in adults",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10825787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=see_link\">",
"      see \"Cyclosporine (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid the herbal medicine St John's wort; take dose at the same time each day; do not allow diluted oral solution to stand before drinking; do not change brands of cyclosporine unless directed by your physician. Patients with psoriasis should avoid excessive sun exposure. Notify physician of severe headache, persistent nausea or vomiting, muscle pain or cramping, unusual swelling of extremities, chest pain, or rapid heartbeat.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10825789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diltiazem has been used to prevent cyclosporine nephrotoxicity, to reduce the frequency of delayed graft function when administered before and after surgery, and to treat the mild hypertension that occurs in most patients after transplantation; diltiazem increases cyclosporine blood concentration by delaying its clearance, resulting in decreased dosage requirements for cyclosporine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Burckart GJ, Canafax DM, and Yee GC, \"Cyclosporine Monitoring,\"",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1986, 20(9):649-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/3530679/pubmed\" id=\"3530679\" target=\"_blank\">",
"        3530679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hardinger KL, Koch MJ, and Brennan DC, \"Current and Future Immunosuppressive Strategies in Renal Transplantation,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2004, 24(9):1159-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/15460177/pubmed\" id=\"15460177\" target=\"_blank\">",
"        15460177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt DW, Mueller EA, Kovarik JM, et al, \"Sandimmune&reg; Neoral&reg; Pharmacokinetics: Impact of the New Oral Formulation,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1995, 27(1):1434-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/7878935/pubmed\" id=\"7878935\" target=\"_blank\">",
"        7878935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin CY and Lee SF, \"Comparison of Pharmacokinetics Between CsA Capsules and Sandimmune&reg; Neoral&reg; in Pediatric Patients,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1994, 26(5):2973-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/7940938/pubmed\" id=\"7940938\" target=\"_blank\">",
"        7940938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niese D, \"A Double-Blind Randomized Study of Sandimmune&reg; Neoral&reg; vs Sandimmune&reg; in New Renal Transplant Recipients: Results After 12 Months,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1995, 27(2):1849-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/7725531/pubmed\" id=\"7725531\" target=\"_blank\">",
"        7725531",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taesch S, Niese D, and Mueller EA, \"Sandimmune&reg; Neoral&reg;, A New Oral Formulation of Cyclosporine With Improved Pharmacokinetic Characteristics: Safety and Tolerability in Renal Transplant Patients,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1994, 26(6):3147-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/7998097/pubmed\" id=\"7998097\" target=\"_blank\">",
"        7998097",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wandstrat TL, Schroeder TJ, and Myre SA, \"Cyclosporine Pharmacokinetics in Pediatric Transplant Recipients,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1989, 11(5):493-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/2683250/pubmed\" id=\"2683250\" target=\"_blank\">",
"        2683250",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yee GC, \"Recent Advances in Cyclosporine Pharmacokinetics,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(5):130S-134S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/55/36729/abstract-text/1745619/pubmed\" id=\"1745619\" target=\"_blank\">",
"        1745619",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15960 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36729=[""].join("\n");
var outline_f35_55_36729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012536\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012539\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012540\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825673\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825602\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012692\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012552\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825603\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012567\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825600\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825674\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012538\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012604\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825675\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825596\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825676\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012607\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012608\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825599\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012556\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012557\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825784\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825785\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825601\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15836546\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825787\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825789\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/26/14756?source=related_link\">",
"      Cyclosporine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/52/6980?source=related_link\">",
"      Cyclosporine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/42/23202?source=related_link\">",
"      Cyclosporine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30858?source=related_link\">",
"      Cyclosporine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/28/40390?source=related_link\">",
"      Cyclosporine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_55_36730="Prognosis of acute myeloid leukemia";
var content_f35_55_36730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis of acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36730/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36730/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36730/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36730/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/55/36730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/55/36730/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/55/36730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid line of cellular development. AML is characterized by a clonal proliferation of myeloid precursors with reduced capacity to differentiate into more mature cellular elements.",
"   </p>",
"   <p>",
"    The response to treatment and overall survival of patients with AML is heterogeneous. A number of prognostic factors related to patient and tumor characteristics have been described for AML, including age, performance status, and karyotype (",
"    <a class=\"graphic graphic_table graphicRef60295 \" href=\"mobipreview.htm?17/14/17643\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review most prognostic factors in AML. Adverse risk factors that are more common in older adults (eg, patients over age 60 years) with AML are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=see_link&amp;anchor=H6273162#H6273162\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Outcomes in older compared with younger patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis, treatment, complications of AML, and further information on specific cytogenetic abnormalities are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several clinical findings that may help predict the likelihood of attaining a complete remission and subsequent disease-free survival in patients with AML. The strongest adverse clinical predictors are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advanced age",
"     </li>",
"     <li>",
"      Poor performance status",
"     </li>",
"     <li>",
"      Cytogenetic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      molecular genetic findings in tumor cells",
"     </li>",
"     <li>",
"      History of exposure to cytotoxic agents or radiation therapy",
"     </li>",
"     <li>",
"      History of prior myelodysplasia or other hematologic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two factors are the main predictors of early death, while the others are better predictors of resistant disease or early relapse. Tumor karyotype and other genetic mutations described in the following sections are strong predictors of resistance to therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Karyotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there is no clearly accepted definition of younger compared to older adults when dealing with AML, in most studies, \"older adults\" was defined as over age 55, 60, or 65 years. Such older adults have lower rates of achieving a complete remission and shorter disease-free survival when compared with younger patients. Higher age appears to act as an adverse prognostic marker even in younger patients.",
"   </p>",
"   <p>",
"    A retrospective analysis of 891 patients &lt;30 years old found that five-year event-free survival (EFS) rates decreased as patient age at diagnosis increased with rates of 54, 46, and 28 percent for children (2 to &lt;13 years), adolescents (13 to &lt;21 years), and young adults (21 to &lt;30 years), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/4\">",
"     4",
"    </a>",
"    ]. With favorable karyotypes excluded, outcomes were superior in children (EFS 44 percent), compared with adolescents (35 percent) and young adults (23 percent).",
"   </p>",
"   <p>",
"    The effect of age on outcome in patients with AML is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=see_link&amp;anchor=H6273162#H6273162\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Outcomes in older compared with younger patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Performance status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most other clinical risk factors in AML are related to comorbidities (eg, heart failure, renal insufficiency, concurrent infection) that can be most easily summarized by the patient's performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. The two most commonly used tools are the Karnofsky performance status and the Eastern Cooperative Oncology Group (ECOG) performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"mobipreview.htm?43/16/44300\">",
"     table 2A-B",
"    </a>",
"    ). Performance status and age at diagnosis can be combined to estimate the percentage of patients who will die within the first 28 days of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/3\">",
"     3",
"    </a>",
"    ]. This ranges from 5 percent for patients under the age of 50 years with an ECOG performance status &lt;3 to 57 percent for patients over age 69 with an ECOG performance status of &ge;3 (",
"    <a class=\"graphic graphic_table graphicRef69209 \" href=\"mobipreview.htm?34/18/35115\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, a retrospective analysis of 968 adults with newly diagnosed AML treated by the Southwest Oncology Group (SWOG) enrolled in prospective trials of induction therapy reported increasing 30-day mortality rate with worsening performance status and increased age at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients &le;65 years of age had 30-day mortality rates of 5, 4, 9, and 21 percent if they presented with an ECOG performance status of 0, 1, 2, or 3, respectively. Patients &gt;65 years had rates of 13, 16, 35, and 60 percent, respectively. Older patients with a worse performance status were also less likely to obtain a complete remission. However, subsequent studies have reported lower rates of short term mortality in older patients, probably due to improvements in supportive care. As an example, a large randomized trial in patients &gt;60 years of age reported a 30-day mortality of approximately 11 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be emphasized that these and other published estimates of outcomes derive from results of patients entered on clinical trials. These trials usually exclude individuals with organ dysfunction and substantially impaired performance status and hence these results may not directly apply to the large fraction of older patients with medical and sometimes psychosocial comorbidities. Indeed, data indicate that the majority of older patients do not receive induction chemotherapy as a consequence of either their refusal of treatment or physician assessment that they would not tolerate or benefit from treatment. Assessment of performance status in AML can be tricky. For example, a patient may have no or minimal symptoms with a PS of 0 or 1 and develop fever and infection and instantly become a PS 3 or 4, depending on the severity of the infection. With proper treatment, they can rapidly revert to baseline. Therefore, many factors may have to be considered when using PS to predict prognosis and it may be that medical co-morbidity indices which include more chronic medical conditions will be more helpful in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Therapy-related AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons who are exposed to cytotoxic agents or radiation therapy are at risk of developing acute myeloid leukemia, myelodysplastic syndrome, and myelodysplastic",
"    <span class=\"nowrap\">",
"     syndrome/myeloproliferative",
"    </span>",
"    neoplasms. These conditions lie along a continuum of disease and are categorized by the 2008 WHO classification system as therapy-related myeloid neoplasms (t-MN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/8\">",
"     8",
"    </a>",
"    ]. T-MNs account for approximately 10 to 20 percent of all cases of AML, MDS, and",
"    <span class=\"nowrap\">",
"     MDS/MPN.",
"    </span>",
"    The incidence among patients treated with cytotoxic agents varies according to the underlying disease, specific agents, timing of exposure, and dose. The prognosis of patients with t-MN is generally worse than for those with de novo AML. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antecedent hematologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-existing myelodysplastic (MDS) or myeloproliferative disorders are common in older patients with AML, occurring in 24 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. These disorders are often associated with ineffective hematopoiesis and dysfunctional blood cells. By the time that AML emerges, these patients may be colonized by pathogenic flora, threatened by recurrent bleeding episodes, and dependent upon transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of race on patient outcomes in AML is uncertain. Using data from seven CALGB studies, it was found that African American and white subjects with AML differ significantly with respect to important risk factors such as cytogenetic risk groups and age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/1\">",
"     1",
"    </a>",
"    ]. African American men had significantly lower rates of complete remission (54 versus 64 percent) and five-year overall survival (16 versus 24 percent) than white men, and may represent a higher risk group. Further studies of this type are needed to confirm these results, suggest possible biologic mechanisms, and provide appropriate high risk treatment programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25245151\">",
"    <span class=\"h1\">",
"     CYTOGENETIC AND MOLECULAR FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25245420\">",
"    <span class=\"h2\">",
"     European LeukemiaNet classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described in more detail below, our understanding regarding the prognostic value of specific cytogenetic and molecular findings in AML is rapidly changing. While initial attempts have been made to incorporate this information into clinical practice, these will undoubtedly change in the future as the impact of combinations of molecular findings is analyzed further. For now, we prefer an approach similar to the classification system initially proposed by the European LeukemiaNet (",
"    <a class=\"graphic graphic_table graphicRef80216 \" href=\"mobipreview.htm?38/37/39516\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/14\">",
"     14",
"    </a>",
"    ]. Given the marked heterogeneity of AML and to allow for some comparability between studies, the European LeukemiaNet has recommended that the outcomes of AML patients enrolled on large prospective trials be reported according to these four defined risk groups. Our approach is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=see_link&amp;anchor=H2#H2\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The European LeukemiaNet integrates cytogenetic and molecular features (ie, FLT3-ITD, CEBPA, and NPM1) in AML to divide cases into four prognostic risk groups (",
"    <a class=\"graphic graphic_table graphicRef80216 \" href=\"mobipreview.htm?38/37/39516\">",
"     table 4",
"    </a>",
"    ). In an analysis of 818 younger adults (&lt;60 years) and 732 older adults with primary AML treated within cooperative group trials, the European LeukemiaNet classification prognostic groups had significantly different rates of complete remission (CR), disease-free survival (DFS), and overall survival (OS) at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Favorable risk &mdash; Among 339 younger adults, rates of CR, DFS, and OS were 96, 55, and 66 percent, respectively. Median DFS and OS were 5.5 and 11.5 years, respectively. Among 145 older adults, rates of CR, DFS, and OS were 83, 24, and 33 percent, respectively. Median DFS and OS were 1.1 and 1.6 years, respectively.",
"     </li>",
"     <li>",
"      Intermediate-I risk &mdash; Among 144 younger adults, rates of CR, DFS, and OS were 76, 23, and 28 percent, respectively. Median DFS and OS were 0.8 and 1.2 years, respectively. Among 136 older adults, rates of CR, DFS, and OS were 61, 10, and 11 percent, respectively. Median DFS and OS were 0.6 and 0.9 years, respectively.",
"     </li>",
"     <li>",
"      Intermediate-II risk &mdash; Among 156 younger adults, rates of CR, DFS, and OS were 79, 34, and 45 percent, respectively. Median DFS and OS were 1.2 and 2.1 years, respectively. Among 222 older adults, rates of CR, DFS, and OS were 63, 11, and 16 percent, respectively. Median DFS and OS were 0.7 and 0.9 years, respectively.",
"     </li>",
"     <li>",
"      Adverse risk &mdash; Among 179 younger adults, rates of CR, DFS, and OS were 50, 10, and 12 percent, respectively. Median DFS and OS were 0.6 and 0.8 years, respectively. Among 229 older adults, rates of CR, DFS, and OS were 39, 6, and 3 percent, respectively. Median DFS and OS were six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study confirms the prognostic value of this classification system. In addition, it offers further insight into the prognosis of AML according to age and tumor characteristics. The distribution of risk differs among younger and older adults, with younger adults having more favorable risk disease (41 versus 20 percent). Within risk groups, older adults had worse outcomes than younger adults. Approximately two-thirds of younger adults and one-third of older adults with favorable risk AML were alive at three years. In contrast, less than 15 percent of all patients with adverse risk disease were alive at three years. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Karyotype",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H649833351\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Karyotype analysis with metaphase cytogenetics is a key component of the initial evaluation of a patient with AML; specific cytogenetic abnormalities in AML have considerable prognostic significance and affect treatment planning (",
"    <a class=\"graphic graphic_table graphicRef70905 \" href=\"mobipreview.htm?26/15/26877\">",
"     table 5",
"    </a>",
"    ). The value of risk stratification by karyotype has been illustrated in several analyses of patients enrolled in prospective clinical trials. The largest studies were cooperative group efforts from the Medical Research Council (MRC), the Southwest Oncology",
"    <span class=\"nowrap\">",
"     Group/Eastern",
"    </span>",
"    Cooperative Oncology Group",
"    <span class=\"nowrap\">",
"     (SWOG/ECOG),",
"    </span>",
"    and the Cancer and Leukemia Group B (CALGB). All studies confirmed earlier results from other groups attesting to the importance of pre-treatment karyotype (",
"    <a class=\"graphic graphic_figure graphicRef65190 \" href=\"mobipreview.htm?16/13/16606\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/16-23\">",
"     16-23",
"    </a>",
"    ]. The following describes methods of grouping karyotype abnormalities by risk of progression. Details regarding specific chromosomal changes and their impact on prognosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specifics regarding what constitutes favorable, intermediate, and unfavorable risk have varied among the cooperative groups. While there has been general agreement that t(8;21), inv(16), and t(15;17) predict a good outcome, there has been disagreement regarding what abnormalities determine an unfavorable risk and how additional chromosomal abnormalities impact the prognostic value of known markers.",
"   </p>",
"   <p>",
"    Information from 5876 adults with newly diagnosed de novo (93 percent) or secondary AML enrolled on prospective Medical Research Council (MRC) trials of intensive anthracycline and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    -based combination chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/23\">",
"     23",
"    </a>",
"    ] was used to modify the MRC&rsquo;s prior stratification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] to create the risk stratification system shown below. Using these definitions, rates of overall survival at 10 years were 69, 38, 33, and 12 percent for patients with favorable risk, normal karyotype, intermediate risk, and adverse risk, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Favorable (approximately 16 percent) &mdash; The following abnormalities are considered favorable, whether alone or in conjunction with other abnormalities: t(8;21), inv(16)(p13;q22), t(16;16)(p13;q22). t(15;17)(q24.1;q21.1) which identifies acute promyelocytic leukemia (APL) is also favorable, but APL is now considered separately from other forms of AML.",
"     </li>",
"     <li>",
"      Normal karyotype (approximately 40 percent)",
"     </li>",
"     <li>",
"      Intermediate (approximately 20 percent) &mdash;abnormalities not described in favorable or unfavorable.",
"     </li>",
"     <li>",
"      Adverse or poor (approximately 25 percent) &mdash; The following abnormalities are considered unfavorable when they occur in cases that",
"      <strong>",
"       do not",
"      </strong>",
"      also contain favorable karyotypic changes: del (5q); add (5q); del (7q); add (7q); monosomies 5 or 7; inv(3)(q21q26); t(3;3)(q21;q26); t(6;11)(q27;q23); t(10;11)(p11-13;q23); t(9;22)(q34;q11); 17p abnormalities or monosomy 17; complex aberrant karyotypes described as at least 4 unrelated abnormalities; 11q23 abnormalities excluding t(9;11)(p21;q23) and excluding t(11;19)(q23;p13); or abnormalities of 3q excluding t(3;5)(q21-25;q31-35).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These survival rates are consistent with those seen by other cooperative groups using similar risk stratification systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. This study also served to clarify the prognostic value of findings that were previously not well understood. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A \"monosomal karyotype,\" defined as at least two autosomal monosomies or a single autosomal monosomy in the presence of one or more structural cytogenetic abnormalities, has been proposed as a better predictor of unfavorable risk disease than a complex karyotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/27\">",
"       27",
"      </a>",
"      ]. The approximately 10 percent of patients with AML who demonstrate a monosomal karyotype have a low rate of complete remission after induction (48 percent) and a &lt;5 percent rate of overall survival at four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. The additional prognostic value of including &lsquo;monosomal karyotype&rsquo; in the adverse risk group was specifically addressed in the analysis of 5876 patients on MRC trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/23\">",
"       23",
"      </a>",
"      ]. While patients with a monosomal karyotype had particularly poor outcomes (&lt;5 percent overall survival at 10 years), 94 percent of cases with a monosomal karyotype were already classified as adverse risk according to the criteria defined above. In at least one retrospective study, the prognostic values of the monosomal karyotype and complex karyotype did not remain when patients with 17p abnormalities or chromosome 5 abnormalities were removed from the analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In two large retrospective analyses, patients with a monosomal karyotype had lower rates of complete remission (CR) and overall survival when compared with patients with unfavorable cytogenetics without a monosomal karyotype [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. The overall outcome for patients with a monosomal karyotype appeared to be better following allogeneic hematopoietic cell transplantation (HCT) when compared with consolidation with chemotherapy alone. The benefit of allogeneic HCT in this population was further supported by an analysis of 305 patients with newly diagnosed AML with a monosomal karyotype enrolled in three consecutive",
"      <span class=\"nowrap\">",
"       HOVON/SAKK",
"      </span>",
"      phase III trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/32\">",
"       32",
"      </a>",
"      ]. CR was achieved in 140 (46 percent) and 107 proceeded with consolidation chemotherapy (48 patients), high dose chemotherapy with autologous stem cell rescue (14 patients), or allogeneic HCT (45 patients). The rates of overall and relapse-free survival at five years were 13 and 12 percent, respectively. None of the 33 patients who achieved a CR but did not proceed to consolidation survived. When compared with the other consolidation options, allogeneic HCT resulted in superior relapse-free (19 versus 9 percent) and overall (17 versus 7 percent) survival at five years. However, it should be noted that the results with allogeneic HCT are also worse in this high risk group because of a high rate of relapse post transplant.",
"     </li>",
"     <li>",
"      Patients with abnormalities of chromosome band 11q23 (seen in 5 to 10 percent of patients with de novo AML and in some patients with therapy related leukemia after topoisomerase II inhibitors) have had a poor outcome when treated with conventional chemotherapy and have previously been included in the adverse risk group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]. Data from the MRC analysis supported prior suggestions that a subset of patients with t(9;11) may be cured with intensive consolidation chemotherapy alone (10 year overall survival rate of 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/23,37,38\">",
"       23,37,38",
"      </a>",
"      ]. As such, patients with this particular 11q23 translocation are",
"      <strong>",
"       not",
"      </strong>",
"      considered to have adverse risk based upon this abnormality.",
"     </li>",
"     <li>",
"      Prior to the MRC analysis, it was not clear how to categorize patients with isolated trisomy 8 with some studies suggesting that these patients had adverse outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/39\">",
"       39",
"      </a>",
"      ] and others reporting that their outcomes did not differ from those with normal cytogenetics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/40\">",
"       40",
"      </a>",
"      ]. The 547 patients with trisomy 8 included in the MRC database had a similar prognosis to those with normal cytogenetics (10-year overall survival in 37 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While patients with cytogenetically normal AML have traditionally been included in the intermediate risk group category, more sophisticated analyses, including gene mutation and microRNA expression studies, suggest that this group is more heterogeneous than previously thought. The effect of gene mutations and microRNA expression on prognosis is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Gene mutations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'MicroRNA expression profiling'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H649833183\">",
"    <span class=\"h3\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar stratification systems to that used in the general population (described above) have also shown prognostic value in older adults with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/9,11,41-44\">",
"     9,11,41-44",
"    </a>",
"    ]. The more favorable translocations seen with core-binding factor AML are considerably less common in older adults. In this population, patients with favorable (7 percent), intermediate (73 percent), or poor risk (20 percent) cytogenetics had complete remission rates of 72, 53 to 63, and 26 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/41\">",
"     41",
"    </a>",
"    ]. Overall survival rates at five years for the same groups were 34, 10 to 15, and 2 percent, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from the Cancer and Leukemia Group B (CALGB) included 42 patients with isolated trisomy 8, 60 percent of whom were more than 60 years of age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/39\">",
"       39",
"      </a>",
"      ]. Median survival was lower in trisomy 8 patients over the age of 60 than in younger patients (4.8 versus 17.5 months) with no long-term survivors among the older patients. The only long-term survivors were those less than 60 years of age who were treated with autologous or allogeneic hematopoietic cell transplantation while in first complete remission. A later CALGB study indicated a five-year overall survival of 7 to 9 percent for the group of patients &gt;60 years of age with trisomy 8 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another CALGB study in patients &ge;60 years of age with AML, the presence of a complex karyotype consisting of three or more chromosome abnormalities in at least one clone or a rare aberration (in the absence of t(8;21) and inv(16)), was associated with five-year disease-free and overall survival rates of 2 percent or less following standard cytotoxic chemotherapy used in conventional doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/45\">",
"       45",
"      </a>",
"      ]. Thus, such patients are better suited for investigational therapy on a clinical trial or supportive care. Similar conclusions were made in a German-Austrian study, in which three-year overall survival for patients &gt;70 years of age with high-risk cytogenetics was 2 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in certain genes (mutations in FLT3, NPM1, KIT) as well as gene expression profiles confer prognostic significance in adult patients with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/46\">",
"     46",
"    </a>",
"    ]. Some of these are discussed below. This is particularly important in the approximately 45 percent of patients with normal karyotypes. This heterogeneous group of patients contains some with a better prognosis (eg, mutations in the myeloid transcription factor gene CEBPA, mutations in the NPM1 gene in the absence of",
"    <span class=\"nowrap\">",
"     FLT3/ITD,",
"    </span>",
"    downregulated HOX expression) as well as others with an adverse prognosis (eg, internal tandem duplications of the tyrosine kinase receptor gene FLT3, high expression of the BAALC gene, overexpression of the ETS-related gene ERG, mutations in IDH1 and IDH2) (",
"    <a class=\"graphic graphic_table graphicRef60295 \" href=\"mobipreview.htm?17/14/17643\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef88091 \" href=\"mobipreview.htm?21/59/22461\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/47-63\">",
"     47-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities in FLT3, NPM1, KIT, and CEBPA have been the most widely studied. Other gene mutations, such as those involving WT1 (Wilms tumor 1), meningioma 1 (MN1), RUNX1, TET2, IDH1, IDH2, DNMT3A, or RAS, may also have prognostic significance, but need further confirmation in prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/64-86\">",
"     64-86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H24780405#H24780405\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Mutations affecting DNA methylation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, it is apparent that the categorization of AML will become more complex in the future with different subgroups containing different combinations of mutations and",
"    <span class=\"nowrap\">",
"     over/under-expression",
"    </span>",
"    of different genes. Hopefully, better understanding of the mechanisms by which these changes produce increased or decreased sensitivity to treatment will evolve, permitting more rational choices of chemotherapy and the selective application of transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     FLT3 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;FLT3 is a transmembrane tyrosine kinase receptor that stimulates cell proliferation upon activation. Mutations in the FMS-like tyrosine kinase 3 gene producing internal transmembrane duplications",
"    <span class=\"nowrap\">",
"     (FLT3/ITD)",
"    </span>",
"    and constitutive activation of the FLT3 receptor tyrosine kinase are quite common in AML, particularly in patients with normal karyotypes, and have been associated with poorer survival in children and in younger and older adults receiving intensive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/52,78,87-97\">",
"     52,78,87-97",
"    </a>",
"    ]. It has been proposed that",
"    <span class=\"nowrap\">",
"     FLT3/ITD",
"    </span>",
"    mutational status is the primary predictor of outcome among patients with intermediate-risk AML by karyotype analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97\">",
"     97",
"    </a>",
"    ]. The exact frequency varies with age with FLT3 mutations being present in approximately 10 and 30 percent of patients with cytogenetically normal AML in the pediatric and adult populations, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/93,98,99\">",
"     93,98,99",
"    </a>",
"    ]. Concurrent abnormalities in other genes, such as NPM1, may influence the impact of the FLT3 mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two main types of FLT3 mutations. The most common are internal tandem duplications of different length that result in ligand-independent activation of the FLT3 receptor and a proliferative signal. Alternatively, point mutations in the activating loop of the kinase domain of FLT3 may result in tyrosine kinase activation of FLT3 in 5 to 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/101,102\">",
"     101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two representative studies of patients with FLT3-ITD have estimated two-year progression-free survival rates of 20 percent and four-year overall survival of approximately 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/52,94\">",
"     52,94",
"    </a>",
"    ]. In contrast, the mutations of the tyrosine kinase domain of FLT3 do not appear to be associated with the same poor outcome as",
"    <span class=\"nowrap\">",
"     FLT3/ITD",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/102\">",
"     102",
"    </a>",
"    ]. Additional characterization of the various types of FLT3 mutations as well as analyses of the clinical impact of differing ratios of",
"    <span class=\"nowrap\">",
"     mutated/wild",
"    </span>",
"    type variants on outcome are in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials with a number of different oral FLT3 tyrosine kinase inhibitors including CEP701 (lestaurtinib),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    malate (SU11248),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and PKC412 (Midostaurin) have been initiated and evidence of antileukemic activity has been seen in phase 2 studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/105-111\">",
"     105-111",
"    </a>",
"    ]. Most responses were incomplete and transient. However, CEP701 and PKC412 can be safely combined with standard AML chemotherapy and randomized trials comparing chemotherapy with or without these FLT3 inhibitors are in progress. Initial results of a phase III trial of induction chemotherapy with or without CEP701 in 224 patients with FLT3 mutant with relapsed or refractory AML reported that the addition of CEP701 failed to increase response rates or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/112\">",
"     112",
"    </a>",
"    ]. Correlative studies found that the FLT3 target was not inhibited in many patients suggesting that a different dose or schedule or more potent agents may be necessary. A dramatic increase in FLT3 ligand after the administration of induction chemotherapy may impair the ability of these drugs to appropriately inhibit their target.",
"   </p>",
"   <p>",
"    The MRC conducted an analysis of the results of both autologous and allogeneic HCT in patients whose leukemia cells were positive for FLT3 ITD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/113\">",
"     113",
"    </a>",
"    ]. This was a retrospective evaluation of large studies of patients who had been randomly assigned to these HCT approaches irrespective of their FLT3 mutational status. In FLT3 ITD positive patients, there was no difference in relapse-free or overall survival between patients allocated to either type of HCT and those treated with chemotherapy alone. However, somewhat conflicting results were seen in similar retrospective analyses conducted by German leukemia groups who noted improved outcomes in FLT3 mutated patients who had a histocompatible sibling donor compared with those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study, the European Group for Blood and Marrow Transplantation (EGBMT) analyzed the outcomes of 206 patients with AML who underwent HLA-identical sibling or matched unrelated HCT in first complete remission after myeloablative conditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/114\">",
"     114",
"    </a>",
"    ]. The 120 patients with FLT3 ITD had a higher median leukocyte count at diagnosis and a shorter interval from complete remission to HCT, but otherwise had similar baseline characteristics to those without FLT3 ITD. The presence of FLT3 ITD was associated with a higher estimated cumulative incidence of relapse at two years (30 versus 16 percent) and a lower two-year leukemia-free survival rate (58 versus 71 percent).",
"   </p>",
"   <p>",
"    It remains unclear whether FLT3 status alone should be used to make recommendations about the use of HCT in first remission. Since there may be heterogeneity in the outcomes of different subtypes of FLT3 mutated patients, further analysis of this subtype, as well as prospective studies, are of importance to help determine their effects on prognosis and possible treatment recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Nucleophosmin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in the nucleophosmin (NPM1) gene are found in approximately 25 and 50 percent of patients with de novo AML or de novo normal karyotype AML, respectively. NPM1 mutations have been associated with improved outcomes in younger and older adults, and children with AML, although the mechanism for increased chemosensitivity is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/1,78,115-119\">",
"     1,78,115-119",
"    </a>",
"    ]. However, concurrent abnormalities in other genes, such as FLT3, influence the impact of the NPM1 mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97,120\">",
"     97,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 215 younger adults with newly diagnosed AML enrolled on prospective Medical Research Council (MRC) trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/23\">",
"       23",
"      </a>",
"      ], patients with a normal karyotype AML and",
"      <span class=\"nowrap\">",
"       FLT3/ITD",
"      </span>",
"      with wild-type NPM1 had a poor prognosis (13 percent alive at 10 years) while patients with NPM1 mutation without FLT3-ITD demonstrated superior survival rates (50 percent alive at 10 years). There were not enough data regarding CEBPA status to analyze its effect on prognosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/94,121-124\">",
"       94,121-124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subjects with a normal karyotype, NPM1 mutations, wild-type FLT3, and low levels of ERG appear to have an especially favorable prognosis, with an estimated two-year progression-free survival of 70 percent after induction treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      followed by intensification with high dose cytarabine or intensification followed by autologous hematopoietic cell transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/52\">",
"       52",
"      </a>",
"      ]. In another study, the four-year overall survival in similar patients was approximately 60 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Older patients with NPM1 mutations also have improved outcomes. As an example, a study from CALGB demonstrated high rates of complete remission and a three-year survival rate of 35 percent in patients whose blasts were NPM1 mutated and FLT3 wild type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/118\">",
"     118",
"    </a>",
"    ]. As such, we have incorporated molecular analysis for NPM1 mutation into the pretreatment assessment evaluation of all patients with newly diagnosed AML, regardless of age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H4#H4\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     CEBPA gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CEBPA",
"    <span class=\"nowrap\">",
"     (CCAAT/enhancer",
"    </span>",
"    binding protein alpha) gene encodes a transcription factor essential for myeloid differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. CEBPA mutations are one of two known mutation types associated with familial leukemia and can be found in approximately 10 percent of patients with newly diagnosed AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97,127\">",
"     97,127",
"    </a>",
"    ]. In addition, 13 to 19 percent of patients with cytogenetically normal AML will have CEBPA mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/48,128-132\">",
"     48,128-132",
"    </a>",
"    ]. Patients with cytogenetically normal AML with CEBPA mutations have a significantly longer median overall survival that is independent of other high-risk molecular features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/78,127,128,133,134\">",
"     78,127,128,133,134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a prospective analysis followed 175 adult patients with newly diagnosed AML with normal cytogenetics who were less than 60 years of age for a median of 4.8 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/127\">",
"     127",
"    </a>",
"    ]. Patients with CEBPA mutations had significantly higher rates of five-year event-free survival (53 versus 30 percent) when compared with those with wild-type CEBPA. In a subset analysis, patients with high-risk molecular features (ie, FLT3-ITD positive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wild-type NPM1) who had mutations in CEBPA had significantly better rates of five-year event-free survival (55 versus 17 percent) and overall survival (58 versus 27 percent) when compared with those with unmutated CEBPA.",
"   </p>",
"   <p>",
"    The favorable effect of CEBPA mutations may be limited to patients who carry two copies of the mutant allele and are negative for FLT3-ITD mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/133,135-138\">",
"     133,135-138",
"    </a>",
"    ]. An international study of 1182 patients with cytogenetically normal AML reported double mutations of CEBPA (either two different mutations or one homozygous mutation) in 91 cases and single mutations in 60 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/132\">",
"     132",
"    </a>",
"    ]. When compared with patients with double mutations of CEBPA, patients with a single CEBPA mutation had higher rates of concurrent mutations in NPM1 (35 versus 3 percent) and FLT3-ITD (30 versus 8 percent). While the presence of any CEBPA mutation was associated with a favorable outcome, only the presence of double mutations of CEBPA was an independent prognostic factor on multivariable analysis. Therefore, the data mentioned above, some of which included patients with only a single mutated allele, may need further study. In addition, there appears to be a separate group of patients in whom CEBPA expression is \"silenced\" by DNA hypermethylation, the prognostic effect of which is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20156658\">",
"    <span class=\"h3\">",
"     IDH genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic mutations in the genes encoding isocitrate dehydrogenase (IDH1 and IDH2) are present in approximately 15 percent of newly diagnosed AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/56-61,97\">",
"     56-61,97",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     IDH1/2",
"    </span>",
"    mutations are mutually exclusive with TET2 and WT1 mutations, and are more commonly seen in cases with NPM1 and DNMT3A mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97\">",
"     97",
"    </a>",
"    ]. Data are conflicting regarding the prognostic impact of IDH gene mutations. In one study, IDH2 mutations appeared to be associated with improved survival, but this benefit was only present in patients with IDH2 R140Q mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97\">",
"     97",
"    </a>",
"    ]. Concurrent abnormalities in",
"    <span class=\"nowrap\">",
"     FLT3/ITD",
"    </span>",
"    appeared to abrogate the beneficial impact of the IDH2 mutation. The clinical importance of this mutation needs to be validated in other series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20155790\">",
"    <span class=\"h3\">",
"     KIT gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the KIT gene can be detected in approximately 6 percent of newly diagnosed AML and in 20 to 30 percent of patients with AML and either t(8;21) or inv(16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97,140,141\">",
"     97,140,141",
"    </a>",
"    ]. While some studies suggest that KIT gene mutations confer a higher risk of relapse and adversely affect overall survival in those with inv(16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/140,141\">",
"     140,141",
"    </a>",
"    ], others suggest that this negative prognostic effect is only seen among AML with t(8;21) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97\">",
"     97",
"    </a>",
"    ]. Screening for KIT mutations might also allow for use of tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , which have in vitro activity against some (but not all) KIT mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/108\">",
"     108",
"    </a>",
"    ]. Clinical trials evaluating the addition of TKIs in selected patients with KIT mutations are beginning.",
"   </p>",
"   <p>",
"    In one study performed in older patients with AML and at least 20 percent of myeloblasts expressing c-Kit, treatment with a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and low-dose cytosine arabinoside was unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/142\">",
"     142",
"    </a>",
"    ]. The presence of KIT mutations was not assessed in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     WT1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wilms tumor 1 gene (WT1) encodes a transcriptional regulator for genes involved in cellular growth and maturation. Disruption of this gene is thought to promote the proliferation of stem cells and disrupt cellular differentiation. Approximately 8 percent of AML cases and 13 percent of patients with cytogenetically normal AML will harbor mutations in WT1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97,143\">",
"     97,143",
"    </a>",
"    ]. Studies investigating the prognostic value of WT1 gene mutations or single nucleotide polymorphisms in cytogenetically normal AML have had mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/64,66,97,143-149\">",
"     64,66,97,143-149",
"    </a>",
"    ]. Some report inferior rates of disease free survival and overall survival in patients with WT1 gene mutations while others do not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is interest in the use of gene expression profiling (GEP) for the diagnosis, classification, and assessment of prognosis in AML, but it is not yet used routinely in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/150-160\">",
"     150-160",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'Acute leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have analyzed leukemia cells from patients with AML and have identified gene \"signatures\" that may be used to distinguish subsets with different outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/151,161-164\">",
"     151,161-164",
"    </a>",
"    ]. Subgroups with different gene expression profiles have been found in patients with normal cytogenetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/165\">",
"     165",
"    </a>",
"    ], as well as those with well defined cytogenetic changes, such as t(8;21) and inv(16) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/166\">",
"     166",
"    </a>",
"    ]. Other groups, such as t(15;17), appeared to be more homogeneous in their \"signature.\"",
"   </p>",
"   <p>",
"    GEP may also be able to identify other groups of AML patients with specific molecular signatures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/152,167\">",
"     152,167",
"    </a>",
"    ]. One cluster, associated with the lowest overall survival and highest cumulative relapse rate after complete remission, had a high frequency of poor prognostic markers (eg, del(7q), del(5q), t(9;22)). Normal CD34+ cells segregated into this cluster, suggesting that the molecular signature of treatment resistance resembles that of normal hematopoietic stem cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/168\">",
"     168",
"    </a>",
"    ]. In another study, AML demonstrating a GEP signature of leukemic stem cells was associated with significantly worse overall survival, independent of other genetic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/169\">",
"     169",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Transformation within primitive multipotent cells'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis of acute myeloid leukemia\", section on 'Leukemic stem cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There was still a wide range of outcomes in the prognostic groupings defined by GEP; accordingly, gene profiling in AML cannot as yet be used as a predictor in individual patients. However, a number of conclusions can be reached from these initial GEP data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They confirm the importance of cytogenetic subgroups of AML as relatively homogeneous diseases, since leukemias with distinct translocations tend to have very similar gene expression patterns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/170\">",
"       170",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They begin to subdivide the large group of patients with normal karyotypes into different biological subsets that appear to have different outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/171\">",
"       171",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      They support other data that suggest the role of a leukemic stem cell in the pathogenesis of AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/169\">",
"       169",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GEP studies may help to identify critical genes and their protein products whose expression could be modified by available drugs or new agents rationally designed to affect these targets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/172\">",
"       172",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GEP may also help to define simpler algorithms incorporating a smaller number of genes, which might be detected using more widely available techniques, such as RT-PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/150,173\">",
"       150,173",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Before these findings can be applied clinically to define subclasses of patients, predict outcome, and perhaps even determine appropriate treatment, they need to be verified in larger groups of patients. In addition, the synthesis and clinical development of drugs to target these heterogeneous molecular changes will be very challenging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     MicroRNA expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNA are short sequences of single-stranded RNA that regulate gene expression. The role of microRNA expression profiling is becoming more prominent in our understanding of the pathogenesis of many cancers, including AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/63,174-182\">",
"     63,174-182",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a small retrospective study which examined clinical outcomes in higher risk (FLT3 mutated, NPM wild type) patients with cytogenetically normal AML reported that different patterns of microRNA expression are associated with varying rates of event-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/174\">",
"     174",
"    </a>",
"    ]. While this was a small retrospective study that requires further confirmation, microRNA expression profiling analysis may lead to clues permitting treatment with agents selectively affecting specific microRNA targets in the future.",
"   </p>",
"   <p>",
"    Another study in 187 younger adults (&lt;60 years) with cytogenetically normal AML noted that patients whose tumors had higher expression of a single microRNA (miR-181a) had higher rates of complete remission and longer overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/183\">",
"     183",
"    </a>",
"    ]. MiR-181a expression maintained its prognostic significance in tumors with FLT3-ITD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NPM1 wild-type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tumor characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor characteristics can affect patient outcome. Characteristics that have been suggested as prognostic markers include the overexpression of drug efflux pumps, apoptosis inhibitors, antigen expression, or factors that lead to cell cycle progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/9,184-195\">",
"     9,184-195",
"    </a>",
"    ]. It is unknown how best to integrate this information into clinical practice at this time. Examples follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     MDR1 phenotype and P-glycoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression of drug efflux pumps (eg, P-glycoprotein) has been associated with poor outcome in patients with AML, particularly in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/184\">",
"     184",
"    </a>",
"    ]. Conflicting observations about the effect of differences in multidrug resistance protein (MRP) expression have been published, perhaps related to the use of different assays. As an example, in one study detection of MRP1 by immunolabeling or RT-PCR failed to show a correlation with treatment outcome, whereas concomitant analysis via a functional assay did show a correlation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/185\">",
"     185",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MDR1 phenotype may emerge during the evolutionary process of the leukemic cells. In a report from the SWOG, 71 percent of older patients with AML expressed MDR1, compared with 30 percent in younger subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients who were MDR1-positive were less likely to have a CR and more likely to have resistant disease. The significance of this finding is unclear, since other studies have indicated that the presence of the MDR-1 phenotype is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/186,187\">",
"     186,187",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/188\">",
"     188",
"    </a>",
"    ] associated with reduced overall survival in AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/189\">",
"     189",
"    </a>",
"    ]. On the other hand, in the SWOG study, older patients who had MDR1-negative AML cells and favorable or intermediate cytogenetics had a high CR rate of 81 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study involving 153 previously untreated patients with AML, positivity for P-glycoprotein (Pgp) did not adversely affect attainment of CR or overall survival unless Pgp was expressed along with lung resistance-related protein (LRP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/190\">",
"     190",
"    </a>",
"    ]. The mean age of this latter sub-population",
"    <span class=\"nowrap\">",
"     (LRP+/Pgp+)",
"    </span>",
"    was 64 years, whereas that of the other groups",
"    <span class=\"nowrap\">",
"     (LRP+/Pgp-,",
"    </span>",
"    <span class=\"nowrap\">",
"     LRP-/Pgp+,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     LRP-/Pgp-)",
"    </span>",
"    was 48 years, indicating that this adverse prognostic combination was more common in the older patient.",
"   </p>",
"   <p>",
"    There are a number of inhibitors of PgP mediated drug efflux that have been evaluated in randomized clinical trials. Unfortunately, these studies did not demonstrate improved outcomes in patients receiving the inhibitors in combination with chemotherapy and in some trials, toxicity was increased as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/196\">",
"     196",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Overexpression of EVI1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecotropic viral integration site 1 (EVI1) is abnormally overexpressed in approximately 8 to 10 percent of AML cases and appears to portend a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/191,192,197\">",
"     191,192,197",
"    </a>",
"    ]. EVI1 appears to interact with DNA methyltransferases that are involved in the epigenetic control of gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/198\">",
"     198",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H24780405#H24780405\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Mutations affecting DNA methylation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a study of 1382 adults less than 60 years of age enrolled on multicenter prospective trials evaluated cases for EVI1 expression by polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/192\">",
"     192",
"    </a>",
"    ]. EVI1 overexpression was detected in 38, 7, and 0.4 percent of cases with unfavorable, intermediate, and favorable risk cytogenetics, respectively. The prognostic effect of EVI1 overexpression was most apparent in the intermediate risk group where overexpression was associated with a significantly lower rate of relapse-free and event-free survival and a nonsignificant trend towards decreased overall survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H11#H11\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 't(3;3) and inv(3) in AML with thrombocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Overexpression of inhibitors of apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overexpression of inhibitors of apoptosis, such as bcl-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/193\">",
"     193",
"    </a>",
"    ] or survivin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/194\">",
"     194",
"    </a>",
"    ], may be associated with poorer outcome. High expression of the co-stimulatory molecule CD40 and the adhesion molecule CD11a have also been associated with a worse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/199\">",
"     199",
"    </a>",
"    ]. In contrast, overexpression of the apoptosis promoter, bax, or a high",
"    <span class=\"nowrap\">",
"     bax/bcl-2",
"    </span>",
"    ratio, was associated with better outcome in two studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/200,201\">",
"     200,201",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27695666\">",
"    <span class=\"h3\">",
"     CD25 expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expression of CD25 (IL-2 receptor alpha) may predict worse outcomes among patients with de novo AML. While initial small retrospective studies suggested that CD25 expression was associated with lower rates of complete remission and worse survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/202,203\">",
"     202,203",
"    </a>",
"    ], its independent predictive value was questioned since CD25 expression has been shown to correlate with FLT3-ITD gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/203\">",
"     203",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The independent prognostic value of CD25 expression in patients with AML was best demonstrated in an analysis of 657 younger adults (&le;60 years) with de novo AML treated in a prospective cooperative group trial (ECOG E1900) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/55/36730/abstract/204\">",
"     204",
"    </a>",
"    ]. Expression of CD25 was identified in 87 patients (13 percent). When compared with CD25 negative tumors, CD25 positive tumors had inferior rates of complete remission and overall survival when stratified by cytogenetic risk group. Among the 75 patients with CD25 expression with mutational analysis results available, 57 (76 percent) demonstrated FLT3-ITD mutations. Among patients with FLT3-ITD mutations, expression of CD25 was associated with shorter median survival (10 versus 25 months) and a lower rate of survival at three years (4 versus 42 percent). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid line of cellular development. AML is characterized by a clonal proliferation of myeloid precursors with reduced capacity to differentiate into more mature cellular elements.",
"     </li>",
"     <li>",
"      The response to treatment and overall survival of patients with AML is heterogeneous. A number of prognostic factors related to patient and tumor characteristics have been described for AML (",
"      <a class=\"graphic graphic_table graphicRef60295 \" href=\"mobipreview.htm?17/14/17643\">",
"       table 1",
"      </a>",
"      ). Of these, patient age at diagnosis, performance status, and karyotype have the most direct effect on treatment at this time and should be a part of the initial evaluation of all patients with newly diagnosed AML. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Karyotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical role of gene mutation analysis, gene expression profiling, and microRNA profiling remains uncertain at this time, although a number of mutations and changes in levels of certain proteins have been shown to have prognostic impact and will likely become part of the \"routine\" characterization of AML in the near future (",
"      <a class=\"graphic graphic_table graphicRef80216 \" href=\"mobipreview.htm?38/37/39516\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/1\">",
"      Sekeres MA, Peterson B, Dodge RK, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004; 103:4036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/2\">",
"      Olesen LH, Aggerholm A, Andersen BL, et al. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling. Br J Haematol 2005; 131:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/3\">",
"      Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001; 92:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/4\">",
"      Creutzig U, B&uuml;chner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 2008; 112:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/5\">",
"      Haferlach T, Schoch C, L&ouml;ffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003; 21:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/6\">",
"      Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/7\">",
"      L&ouml;wenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/9\">",
"      Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89:3323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/10\">",
"      Manoharan A, Baker RI, Kyle PW. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. Am J Hematol 1997; 55:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/11\">",
"      Wahlin A, Markev&auml;rn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/12\">",
"      Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998; 21:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/13\">",
"      Bello C, Yu D, Komrokji RS, et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011; 117:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/14\">",
"      D&ouml;hner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/15\">",
"      Mr&oacute;zek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30:4515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/16\">",
"      Ferrant A, Doyen C, Delannoy A, et al. Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant 1995; 15:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/17\">",
"      Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/18\">",
"      Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58:4173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/19\">",
"      Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/20\">",
"      Byrd JC, Mr&oacute;zek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100:4325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/21\">",
"      Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003; 102:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/22\">",
"      Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22:3741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/23\">",
"      Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/24\">",
"      Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/25\">",
"      Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/26\">",
"      Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006; 135:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/27\">",
"      Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/28\">",
"      Kayser S, Zucknick M, D&ouml;hner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood 2012; 119:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/29\">",
"      Middeke JM, Beelen D, Stadler M, et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood 2012; 120:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/30\">",
"      Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010; 116:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/31\">",
"      Fang M, Storer B, Estey E, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood 2011; 118:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/32\">",
"      Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 2012; 30:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/33\">",
"      Moorman AV, Hagemeijer A, Charrin C, et al. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3): a cytogenetic and clinical profile of 53 patients. European 11q23 Workshop participants. Leukemia 1998; 12:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/34\">",
"      Swansbury GJ, Slater R, Bain BJ, et al. Hematological malignancies with t(9;11)(p21-22;q23)--a laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia 1998; 12:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/35\">",
"      Krauter J, Wagner K, Sch&auml;fer I, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009; 27:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/36\">",
"      Forrest DL, Nevill TJ, Horsman DE, et al. Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities. Br J Haematol 1998; 103:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/37\">",
"      Samuels BL, Larson RA, Le Beau MM, et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/38\">",
"      Baer MR, Stewart CC, Lawrence D, et al. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia 1998; 12:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/39\">",
"      Byrd JC, Lawrence D, Arthur DC, et al. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461. Clin Cancer Res 1998; 4:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/40\">",
"      Wolman SR, Gundacker H, Appelbaum FR, et al. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood 2002; 100:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/41\">",
"      Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/42\">",
"      Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/43\">",
"      Fr&ouml;hling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 108:3280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/44\">",
"      Knipp S, Hildebrand B, K&uuml;ndgen A, et al. Intensive chemotherapy is not recommended for patients aged &gt;60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007; 110:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/45\">",
"      Cancer and Leukemia Group B 8461, Farag SS, Archer KJ, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/46\">",
"      Santamar&iacute;a CM, Chill&oacute;n MC, Garc&iacute;a-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009; 114:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/47\">",
"      Marcucci G, Mr&oacute;zek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005; 12:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/48\">",
"      Bienz M, Ludwig M, Leibundgut EO, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/49\">",
"      Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23:9234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/50\">",
"      Monzo M, Brunet S, Urbano-Ispizua A, et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006; 107:4871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/51\">",
"      Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood 2006; 108:4146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/52\">",
"      Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007; 25:3337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/53\">",
"      Langer C, Radmacher MD, Ruppert AS, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008; 111:5371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/54\">",
"      Andreeff M, Ruvolo V, Gadgil S, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia 2008; 22:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/55\">",
"      Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009; 27:5031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/56\">",
"      Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/57\">",
"      Wagner K, Damm F, G&ouml;hring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010; 28:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/58\">",
"      Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28:3636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/59\">",
"      Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010; 116:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/60\">",
"      Green CL, Evans CM, Hills RK, et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010; 116:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/61\">",
"      Schnittger S, Haferlach C, Ulke M, et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010; 116:5486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/62\">",
"      Schwind S, Marcucci G, Maharry K, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:5660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/63\">",
"      Eisfeld AK, Marcucci G, Maharry K, et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 120:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/64\">",
"      Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008; 26:4595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/65\">",
"      Neubauer A, Maharry K, Mr&oacute;zek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26:4603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/66\">",
"      Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26:5429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/67\">",
"      Heuser M, Beutel G, Krauter J, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108:3898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/68\">",
"      Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007; 21:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/69\">",
"      Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113:5951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/70\">",
"      Langer C, Marcucci G, Holland KB, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2009; 27:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/71\">",
"      Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114:5352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/72\">",
"      Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood 2011; 117:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/73\">",
"      Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 2011; 29:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/74\">",
"      Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/75\">",
"      Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/76\">",
"      Thol F, Damm F, L&uuml;deking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011; 29:2889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/77\">",
"      Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/78\">",
"      Rockova V, Abbas S, Wouters BJ, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011; 118:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/79\">",
"      Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011; 118:3803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/80\">",
"      Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011; 118:5593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/81\">",
"      Hou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/82\">",
"      Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/83\">",
"      Gaidzik VI, Paschka P, Sp&auml;th D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J Clin Oncol 2012; 30:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/84\">",
"      Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012; 119:5824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/85\">",
"      Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 2012; 30:3109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/86\">",
"      Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012; 120:2963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/87\">",
"      Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/88\">",
"      Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol 2003; 122:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/89\">",
"      Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61:7233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/90\">",
"      Fr&ouml;hling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100:4372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/91\">",
"      Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003; 102:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/92\">",
"      Pollard JA, Alonzo TA, Gerbing RB, et al. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. Blood 2006; 108:2764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/93\">",
"      Artz A, Dong X. Defining anemia by race using epidemiologic data. Blood 2008; 111:2941; author reply 2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/94\">",
"      Schlenk RF, D&ouml;hner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/95\">",
"      Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009; 114:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/96\">",
"      Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:3622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/97\">",
"      Patel JP, G&ouml;nen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/98\">",
"      Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/99\">",
"      Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood 2006; 108:3654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/100\">",
"      Schneider F, Hoster E, Unterhalt M, et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood 2012; 119:4383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/101\">",
"      Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/102\">",
"      Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. Blood 2008; 111:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/103\">",
"      Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008; 111:4788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/104\">",
"      Borthakur G, Kantarjian H, Patel KP, et al. Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 2012; 118:5819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/105\">",
"      Fiedler W, Serve H, D&ouml;hner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/106\">",
"      Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/107\">",
"      Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103:3669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/108\">",
"      Kolitz JE. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 2006; 134:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/109\">",
"      Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006; 108:3262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/110\">",
"      Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/111\">",
"      Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28:4339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/112\">",
"      Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117:3294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/113\">",
"      Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005; 106:3658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/114\">",
"      Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012; 30:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/115\">",
"      Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 109:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/116\">",
"      Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia 2009; 23:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/117\">",
"      Schneider F, Hoster E, Unterhalt M, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 2009; 113:5250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/118\">",
"      Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/119\">",
"      Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011; 117:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/120\">",
"      Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 2009; 114:3024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/121\">",
"      D&ouml;hner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106:3740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/122\">",
"      Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106:3747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/123\">",
"      Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107:4011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/124\">",
"      Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/125\">",
"      Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/126\">",
"      Eyholzer M, Schmid S, Wilkens L, et al. The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer 2010; 103:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/127\">",
"      Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26:5078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/128\">",
"      Fr&ouml;hling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/129\">",
"      Pabst T, Eyholzer M, Haefliger S, et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008; 26:5088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/130\">",
"      Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/131\">",
"      Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2009; 113:6558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/132\">",
"      Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/133\">",
"      Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009; 113:5090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/134\">",
"      Bacher U, Schnittger S, Macijewski K, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood 2012; 119:4719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/135\">",
"      Wouters BJ, L&ouml;wenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113:3088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/136\">",
"      Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009; 100:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/137\">",
"      Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/138\">",
"      Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28:2739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/139\">",
"      Figueroa ME, Wouters BJ, Skrabanek L, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 2009; 113:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/140\">",
"      Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24:3904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/141\">",
"      L&uuml;ck SC, Russ AC, Du J, et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol 2010; 148:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/142\">",
"      Heidel F, Cortes J, R&uuml;cker FG, et al. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer 2007; 109:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/143\">",
"      Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009; 113:4505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/144\">",
"      Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009; 115:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/145\">",
"      Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27:5195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/146\">",
"      Damm F, Heuser M, Morgan M, et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010; 28:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/147\">",
"      Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010; 115:5222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/148\">",
"      Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2010; 116:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/149\">",
"      Becker H, Marcucci G, Maharry K, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/150\">",
"      Lacayo NJ, Meshinchi S, Kinnunen P, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004; 104:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/151\">",
"      Bullinger L, D&ouml;hner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/152\">",
"      Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/153\">",
"      Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 2006; 108:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/154\">",
"      R&uuml;cker FG, Bullinger L, Schwaenen C, et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006; 24:3887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/155\">",
"      Hess CJ, Berkhof J, Denkers F, et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol 2007; 25:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/156\">",
"      Bullinger L, D&ouml;hner K, Kranz R, et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008; 111:4490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/157\">",
"      Bacher U, Kohlmann A, Haferlach T. Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol 2009; 145:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/158\">",
"      Powell JA, Thomas D, Barry EF, et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood 2009; 114:4859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/159\">",
"      Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010; 28:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/160\">",
"      Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/161\">",
"      Metzeler KH, Hummel M, Bloomfield CD, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008; 112:4193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/162\">",
"      Silva FP, Swagemakers SM, Erpelinck-Verschueren C, et al. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. Blood 2009; 114:3001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/163\">",
"      de Jonge HJ, Valk PJ, Veeger NJ, et al. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010; 116:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/164\">",
"      Li Z, Herold T, He C, et al. Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative Study. J Clin Oncol 2013; 31:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/165\">",
"      Radmacher MD, Marcucci G, Ruppert AS, et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 2006; 108:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/166\">",
"      Bullinger L, R&uuml;cker FG, Kurz S, et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/167\">",
"      de Jonge HJ, de Bont ES, Valk PJ, et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 2009; 114:2869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/168\">",
"      van Rhenen A, Feller N, Kelder A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11:6520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/169\">",
"      Greaves M. Cancer stem cells renew their impact. Nat Med 2011; 17:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/170\">",
"      Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005; 106:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/171\">",
"      Mr&oacute;zek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/172\">",
"      Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/173\">",
"      Sakhinia E, Faranghpour M, Liu Yin JA, et al. Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol 2005; 130:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/174\">",
"      Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/175\">",
"      Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/176\">",
"      Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111:5078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/177\">",
"      Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007; 104:19971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/178\">",
"      Li Z, Lu J, Sun M, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008; 105:15535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/179\">",
"      Havelange V, Garzon R, Croce CM. MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer 2009; 101:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/180\">",
"      Garzon R, Heaphy CE, Havelange V, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114:5331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/181\">",
"      Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood 2010; 116:5316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/182\">",
"      Marcucci G, Mr&oacute;zek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/183\">",
"      Schwind S, Maharry K, Radmacher MD, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28:5257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/184\">",
"      Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/185\">",
"      Legrand O, Simonin G, Perrot JY, et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91:4480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/186\">",
"      Kar&aacute;szi E, Jakab K, Homolya L, et al. Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br J Haematol 2001; 112:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/187\">",
"      Schaich M, Soucek S, Thiede C, et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/188\">",
"      Schaich M, Ritter M, Illmer T, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001; 112:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/189\">",
"      Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/190\">",
"      Tsuji K, Motoji T, Sugawara I, et al. Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol 2000; 110:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/191\">",
"      Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/192\">",
"      Gr&ouml;schel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/193\">",
"      Campos L, Oriol P, Sabido O, Guyotat D. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. Leuk Lymphoma 1997; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/194\">",
"      Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000; 111:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/195\">",
"      Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med 2010; 16:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/196\">",
"      Kolitz JE, George SL, Marcucci G, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010; 116:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/197\">",
"      Gr&ouml;schel S, Schlenk RF, Engelmann J, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol 2013; 31:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/198\">",
"      Lugthart S, Figueroa ME, Bindels E, et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 2011; 117:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/199\">",
"      Brouwer RE, Hoefnagel J, Borger van Der Burg B, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol 2001; 115:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/200\">",
"      Ong YL, McMullin MF, Bailie KE, et al. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol 2000; 111:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/201\">",
"      Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/202\">",
"      Nakase K, Kita K, Otsuji A, et al. Diagnostic and clinical importance of interleukin-2 receptor alpha chain expression on non-T-cell acute leukaemia cells. Br J Haematol 1992; 80:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/203\">",
"      Terwijn M, Feller N, van Rhenen A, et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer 2009; 45:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/55/36730/abstract/204\">",
"      G&ouml;nen M, Sun Z, Figueroa ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012; 120:2297.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4516 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-1401E7A8BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36730=[""].join("\n");
var outline_f35_55_36730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Performance status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Therapy-related AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antecedent hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25245151\">",
"      CYTOGENETIC AND MOLECULAR FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25245420\">",
"      European LeukemiaNet classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Karyotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H649833351\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H649833183\">",
"      - Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gene mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - FLT3 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Nucleophosmin gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - CEBPA gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20156658\">",
"      - IDH genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20155790\">",
"      - KIT gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - WT1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MicroRNA expression profiling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tumor characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - MDR1 phenotype and P-glycoprotein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Overexpression of EVI1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Overexpression of inhibitors of apoptosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27695666\">",
"      - CD25 expression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4516|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/13/16606\" title=\"figure 1\">",
"      Survival AML cytogenetic risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/14/17643\" title=\"table 1\">",
"      Prognostic factors AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/11/2236\" title=\"table 2A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/18/35115\" title=\"table 3\">",
"      Death during induction AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/37/39516\" title=\"table 4\">",
"      AML Risk Stratification European LeukemiaNet 2010",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/15/26877\" title=\"table 5\">",
"      Recurring karyotypic abnormalities in AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/59/22461\" title=\"table 6\">",
"      Molecular markers in AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=related_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/33/35354?source=related_link\">",
"      Pathogenesis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17274?source=related_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/47/43768?source=related_link\">",
"      Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_55_36731="Antithyroid drug controversies";
var content_f35_55_36731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Controversies about antithyroid drug use",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Controversy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Best available answer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For how long should patients be treated?",
"       </td>",
"       <td>",
"        12-18 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the dose influence the chances of remission?",
"       </td>",
"       <td>",
"        Probably not",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do higher doses bring the disease under more rapid control?",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the coadministration or subsequent use of T4 or T3 improve remission rates?",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Are there baseline predictors of the likelihood of remission?",
"       </td>",
"       <td>",
"        Severe disease, large goiter, high anti-TSH receptor antibody titers may be predictive of failure, but only in extreme cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does pretreatment with antithyroid drugs decrease the chances",
"of thyroid storm or other adverse outcomes after radioiodine therapy?",
"       </td>",
"       <td>",
"        Possibly, but only because thyroid hormone levels are lower after therapy in those few patients who exhibit an exacerbation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Will antithyroid drug therapy after radioiodine lead to more rapid disease control?",
"       </td>",
"       <td>",
"        PTU, no (at 6 wk); methimazole, yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Cooper DC. Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab 2003; 88:3474. file://jcem.endojournals.org/. Copyright &copy; 2003 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36731=[""].join("\n");
var outline_f35_55_36731=null;
var title_f35_55_36732="Who should be tested LTBI";
var content_f35_55_36732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Who should be tested for latent TB infection?*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Those with increased risk of new TB infection (all patients should be tested regardless of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Close contacts of patients with active pulmonary/respiratory TB&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Casual contacts of patients with highly contagious active TB&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Healthcare workers and other occupations in which there is risk of exposure to patients with untreated contagious active TB (prison facilities, homeless shelters)&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Those with increased risk of reactivation&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High risk (all patients should be tested regardless of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV infection (any stage of illness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transplant, chemotherapy, or other major immunocompromising condition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphoma, leukemia, head&nbsp;and neck cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal chest x-ray with apical fibronodular changes typical of healed TB (not including granuloma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Silicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal failure (requiring dialysis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treatment with TNF-alpha inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Moderate risk (patients under age 65 should be tested)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic glucocorticoids (&ge;15 mg/day for &ge;1 month)&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Slightly increased risk (patients under age 50 should be tested)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Underweight (&lt;85 percent of ideal body weight); for most individuals this is equivalent to body mass index (BMI) &le;20.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cigarette smoker (1 pack/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chest x-ray with solitary granuloma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive.",
"     <br>",
"      &bull; A second test is warranted if the first test is negative (see text).",
"      <br>",
"       &Delta; Baseline two-step testing should be performed, followed by annual testing.",
"       <br>",
"        &loz; Generally need a single test.",
"        <br>",
"         &sect; The US Centers for Disease Control and&nbsp;Prevention&nbsp;(CDC) recommends skin testing for all patients in this category. However, population based studies demonstrate that the relative risk for development of active tuberculosis in this category is moderate (2-4x that of healthy individuals). Therefore, an age cutoff of &le;65 is indicated, so that potential risks of INH toxicity in older patients do not outweigh potential benefit. (See separate table summarizing relative risk for development of active tuberculosis).",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36732=[""].join("\n");
var outline_f35_55_36732=null;
var title_f35_55_36733="TNM stage oropharynx";
var content_f35_55_36733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the oropharynx",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor 2 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 2 cm but not more than 4 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 4 cm in greatest dimension or extension to lingual surface of epiglottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a lymph node more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx.",
"     <br>",
"      &bull; Metastases at level VII are considered regional lymph node metastases.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36733=[""].join("\n");
var outline_f35_55_36733=null;
var title_f35_55_36734="Mechanisms involved in persistent diarrhea";
var content_f35_55_36734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Explanatory mechanisms for persistent diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 485px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several different mechanisms can explain the development of persistent diarrhea following an episode of acute diarrhea: 1. A secondary event such as lactose intolerance or bacterial overgrowth develops during the acute episode and causes the symptoms to persist. 2. Because of special pathogen characteristics, the infectious agent is never cleared and causes prolonged illness. 3. Because of weakness in defenses (eg, immunosuppression or poor intestinal regeneration) the host is unable to efficiently clear the pathogen and recovery is delayed. 4. Multiple new infections with separate pathogens cause continued symptoms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Penny ME. Commentary. Pediatr Infect Dis J 1993; 12:762. Copyright &copy; 1993 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36734=[""].join("\n");
var outline_f35_55_36734=null;
var title_f35_55_36735="Cervical wedge fracture";
var content_f35_55_36735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cervical anterior wedge fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_55_36735=[""].join("\n");
var outline_f35_55_36735=null;
